

BENZAMIDE 2-HYDROXY-3-DIAMINOALKANES

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. provisional application serial no. 60/464,687, filed April 21, 2003, which
5 is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to benzamide 2-hydroxy-3-
10 diaminoalkanes and to such compounds that are useful in the treatment of Alzheimer's disease and related diseases. More specifically, it relates to such compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A beta), a
15 major component of the amyloid plaques found in the brains of Alzheimer's sufferers.

Background of the Invention

Alzheimer's disease (AD) is a progressive degenerative disease of the brain primarily associated with aging.
20 Clinical presentation of AD is characterized by loss of memory, cognition, reasoning, judgment, and orientation. As the disease progresses, motor, sensory, and linguistic abilities are also affected until there is global impairment of multiple cognitive functions. These cognitive losses occur
25 gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years.

Alzheimer's disease is characterized by two major pathologic observations in the brain: neurofibrillary tangles and beta amyloid (or neuritic) plaques, comprised
30 predominantly of an aggregate of a peptide fragment known as A beta. Individuals with AD exhibit characteristic beta-amyloid deposits in the brain (beta amyloid plaques) and in cerebral blood vessels (beta amyloid angiopathy) as well as neurofibrillary tangles. Neurofibrillary tangles occur not
35 only in Alzheimer's disease but also in other dementia-

inducing disorders. On autopsy, large numbers of these lesions are generally found in areas of the human brain important for memory and cognition.

5 Smaller numbers of these lesions in a more restricted anatomical distribution are found in the brains of most aged humans who do not have clinical AD. Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), and other neurodegenerative disorders. Beta-amyloid is a
10 defining feature of AD, now believed to be a causative precursor or factor in the development of disease. Deposition of A beta in areas of the brain responsible for cognitive activities is a major factor in the development of AD. Beta-amyloid plaques are predominantly composed of amyloid beta
15 peptide (A beta, also sometimes designated betaA4). A beta peptide is derived by proteolysis of the amyloid precursor protein (APP) and is comprised of 39-42 amino acids. Several proteases called secretases are involved in the processing of
20 APP.

Cleavage of APP at the N-terminus of the A beta peptide by beta-secretase and at the C-terminus by one or more gamma-secretases constitutes the beta-amyloidogenic pathway, i.e. the pathway by which A beta is formed. Cleavage of APP by
25 alpha-secretase produces alpha-sAPP, a secreted form of APP that does not result in beta-amyloid plaque formation. This alternate pathway precludes the formation of A beta peptide. A description of the proteolytic processing fragments of APP is found, for example, in U.S. Patent Nos. 5,441,870;
30 5,721,130; and 5,942,400.

An aspartyl protease has been identified as the enzyme responsible for processing of APP at the beta-secretase cleavage site. The beta-secretase enzyme has been disclosed using varied nomenclature, including BACE, Asp, and Memapsin.

See, for example, Sinha et al., 1999, *Nature* 402:537-554 (p501) and published PCT application W000/17369.

Several lines of evidence indicate that progressive cerebral deposition of beta-amyloid peptide (A beta) plays a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades. See, for example, Selkoe, 1991, *Neuron* 6:487. Release of A beta from neuronal cells grown in culture and the presence of A beta in cerebrospinal fluid (CSF) of both normal individuals and AD patients has been demonstrated. See, for example, Seubert et al., 1992, *Nature* 359:325-327.

It has been proposed that A beta peptide accumulates as a result of APP processing by beta-secretase, thus inhibition of this enzyme's activity is desirable for the treatment of AD. *In vivo* processing of APP at the beta-secretase cleavage site is thought to be a rate-limiting step in A beta production, and is thus a therapeutic target for the treatment of AD. See for example, Sabbagh, M., et al., 1997, *Alz. Dis. Rev.* 3, 1-19.

BACE1 knockout mice fail to produce A beta, and present a normal phenotype. When crossed with transgenic mice that over express APP, the progeny show reduced amounts of A beta in brain extracts as compared with control animals (Luo et al., 2001 *Nature Neuroscience* 4:231-232). This evidence further supports the proposal that inhibition of beta-secretase activity and reduction of A beta in the brain provides a therapeutic method for the treatment of AD and other beta amyloid disorders.

At present there are no effective treatments for halting, preventing, or reversing the progression of Alzheimer's disease. Therefore, there is an urgent need for pharmaceutical agents capable of slowing the progression of Alzheimer's disease and/or preventing it in the first place.


Compounds that are effective inhibitors of beta-secretase, that inhibit beta-secretase-mediated cleavage of

APP, that are effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques, are needed for the treatment and prevention of disease characterized by amyloid beta deposits or plaques, such as AD.

SUMMARY OF THE INVENTION

The invention encompasses the compounds of formula (I) shown below, pharmaceutical compositions containing the compounds and methods employing such compounds or compositions in the treatment of Alzheimer's disease and more specifically compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce A-beta peptide, a major component of the amyloid plaques found in the brains of Alzheimer's sufferers.

In a broad aspect, the invention provides compounds of formula I



and pharmaceutically acceptable salts or esters thereof, wherein Z is aryl, heteroaryl or heterocyclyl, wherein said groups are optionally substituted with 1 or 2 R_B groups, wherein,

where R_B at each occurrence is independently selected from halogen, -OH, -OCF₃, -O-phenyl, -CN, -NR₁₀₀R₁₀₁, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, (CH₂)₀₋₃(C₃-C₇ cycloalkyl), aryl, heteroaryl, or heterocyclyl wherein, the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, or heterocyclyl groups are optionally substituted with 1 or 2 substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, halogen, -OH, -CN, or -NR₁₀₀R₁₀₁;

where R_{100} and R_{101} are at each occurrence are independently H, C_1 - C_6 alkyl, or phenyl;

X is $-(C=O)-$ or $-(SO_2)-$

R_1 is C_1 - C_{10} alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, $-OH$, $=O$, $-SH$, $-CN$, $-CF_3$, $-OCF_3$, $-C_{3-7}$ cycloalkyl, $-C_1$ - C_4 alkoxy, amino, mono-dialkylamino, aryl, heteroaryl, heterocycloalkyl, wherein each aryl group is optionally substituted with 1, 2 or 3 R_{50} groups;

wherein R_{50} is selected from halogen, OH , SH , CN , $-CO-(C_1-C_4 \text{ alkyl})$, $-NR_7R_8$, $-S(O)_{0-2}-(C_1-C_4 \text{ alkyl})$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl;

wherein the alkyl, alkenyl, alkynyl, alkoxy and cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_1 - C_4 alkyl, halogen, OH , $-NR_5R_6$, CN , C_1 - C_4 haloalkoxy, NR_7R_8 , and C_1 - C_4 alkoxy;

wherein R_5 and R_6 are independently H or C_1 - C_6 alkyl; or

wherein R_5 and R_6 and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring; and

wherein R_7 and R_8 are independently selected from the group consisting of H; $-C_1$ - C_4 alkyl optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of $-OH$, $-NH_2$, and halogen; $-C_3$ - C_6 cycloalkyl; $-(C_1$ - $C_4 \text{ alkyl})-O-(C_1$ - $C_4 \text{ alkyl})$; $-C_2$ - C_4 alkenyl; and $-C_2$ - C_4 alkynyl;

wherein each heteroaryl is optionally substituted with 1 or 2 R_{50} groups;

wherein each heterocycloalkyl group is optionally substituted with 1 or 2 groups that are independently R_{50} or $=O$;

R₂ and R₃ are independently selected from

-H;

-F;

5 -C₁-C₆ alkyl optionally substituted with a substituent
selected from the group consisting of -F, -OH, -C≡N, -
CF₃, C₁-C₃ alkoxy, and -NR₅R₆;

-(CH₂)₀₋₂-R₁₇;

-(CH₂)₀₋₂-R₁₈;

10 -C₂-C₆ alkenyl or C₂-C₆ alkynyl, wherein each is optionally
substituted with an independent substituent selected from
the group consisting of -F, -OH, -C≡N, -CF₃ and C₁-C₃
alkoxy;

15 -(CH₂)₀₋₂-C₃-C₇ cycloalkyl, optionally substituted an
independent substituent selected from the group
consisting of -F, -OH, -C≡N, -CF₃, C₁-C₃ alkoxy and -NR₅R₆;
or

20 R₂, R₃ and the carbon to which they are attached form a
carbocycle of three thru seven carbon atoms, wherein one
carbon atom is optionally replaced by a group selected from -
O-, -S-, -SO₂-, or -NR₇-;

25 where R₁₇ at each occurrence is an aryl group
selected from phenyl, 1-naphthyl, 2-naphthyl ,
indanyl, indenyl, dihydronaphthyl and tetralinyl,
wherein said aryl groups are optionally substituted
with one or two groups that are independently

30 -C₁-C₃ alkyl; -C₁-C₄ alkoxy; CF₃; or
-C₂-C₆ alkenyl or -C₂-C₆ alkynyl each of which is
optionally substituted with one substituent selected
from the group consisting of F, OH, C₁-C₃ alkoxy; or
-halogen;

-OH;

-C≡N;

-C₃-C₇ cycloalkyl;

-CO-(C₁-C₄ alkyl);

35 -SO₂-(C₁-C₄ alkyl);

where R_{18} is a heteroaryl group selected from pyridinyl, pyrimidinyl, quinolinyl, indolyl, pyridazinyl, pyrazinyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, furanyl, thienyl, pyrrolyl, oxadiazolyl or thiadiazolyl, wherein each of said heteroaryl groups is optionally substituted with one or two groups that are independently

- C_1 - C_6 alkyl optionally substituted with one substituent selected from the group consisting of OH, $C\equiv N$, CF_3 , C_1 - C_3 alkoxy, and $-NR_5R_6$;

R_{15} is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy C_1 - C_6 alkyl, hydroxy C_1 - C_6 alkyl, halo C_1 - C_6 alkyl, each of which is unsubstituted or substituted with 1, 2, 3, or 4 groups independently selected from halogen, C_1 - C_6 alkyl, hydroxy, C_1 - C_6 alkoxy, NH_2 , and $-R_{26}-R_{27}$;

wherein R_{26} is selected from the group consisting of a bond, $-C(O)-$, $-SO_2-$, $-CO_2-$, $-C(O)NR_5-$, and $-NR_5C(O)-$,

wherein R_{27} is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, aryl C_1 - C_6 alkyl, heterocycloalkyl, and heteroaryl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen, haloalkyl, hydroxyalkyl, $-NR_5R_6$, $-C(O)NR_5R_6$;

R_C is selected from the group consisting of $-(CH_2)_{0-3}-(C_3-C_8)$ cycloalkyl wherein the cycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from the group consisting of $-R_{205}$, $-CO_2-(C_1-C_4$ alkyl), and aryl, wherein aryl is optionally substituted with 1 or 2 independently selected R_{200} groups;

$-(CR_{245}R_{250})_{0-4}$ -aryl;

- (CR₂₄₅R₂₅₀)₀₋₄-heteroaryl;
- (CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl;
- (CR₂₄₅R₂₅₀)₀₋₄-aryl-heteroaryl;
- (CR₂₄₅R₂₅₀)₀₋₄-aryl-heterocycloalkyl;
- 5 - (CR₂₄₅R₂₅₀)₀₋₄-aryl-aryl;
- (CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-aryl;
- (CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heterocycloalkyl;
- (CR₂₄₅R₂₅₀)₀₋₄-heteroaryl-heteroaryl;
- (CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heteroaryl;
- 10 - (CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-heterocycloalkyl;
- (CR₂₄₅R₂₅₀)₀₋₄-heterocycloalkyl-aryl;
- a monocyclic or bicyclic ring of 5, 6, 7 8, 9, or 10 carbons
 fused to 1 or 2 aryl, heteroaryl, or heterocycloalkyl groups
 wherein 1, 2 or 3 carbons of the monocyclic or bicyclic ring
15 is optionally replaced with
 - NH,
 - N(CO)₀₋₁R₂₁₅,
 - N(CO)₀₋₁R₂₂₀,
 - O, or
 - 20 -S(=O)₀₋₂, and wherein the monocyclic or bicyclic ring is optionally
 substituted with 1, 2 or 3 groups that are independently
 -R₂₀₅, -R₂₄₅, -R₂₅₀ or =O;
- C₂-C₆ alkenyl optionally substituted with 1, 2, or 3 R₂₀₅
25 groups;
- C₂-C₆ alkynyl optionally substituted with 1, 2, or 3 R₂₀₅
 groups;
- wherein each aryl group attached directly or indirectly
 to the -(CR₂₄₅R₂₅₀)₀₋₄ group is optionally substituted with
30 1, 2, 3 or 4 R₂₀₀ groups;
- wherein each heteroaryl group attached directly or
 indirectly to the -(CR₂₄₅R₂₅₀)₀₋₄ group is optionally
 substituted with 1, 2, 3, or 4 R₂₀₀;

wherein each heterocycloalkyl attached directly or indirectly to the $-(CR_{245}R_{250})_{0-4}$ group is optionally substituted with 1, 2, 3, or 4 R_{210} ;

wherein R_{200} at each occurrence is independently selected
5 from the group consisting of

$-C_1-C_6$ alkyl optionally substituted with 1, 2, or 3 R_{205} groups;

$-OH$;

$-NO_2$;

10 $-halogen$;

$-C\equiv N$;

$-(CH_2)_{0-4}-CO-NR_{220}R_{225}$;

$-(CH_2)_{0-4}-CO-(C_1-C_8 \text{ alkyl})$;

$-(CH_2)_{0-4}-CO-(C_2-C_8 \text{ alkenyl})$;

15 $-(CH_2)_{0-4}-CO-(C_2-C_8 \text{ alkynyl})$;

$-(CH_2)_{0-4}-CO-(C_3-C_7 \text{ cycloalkyl})$;

$-(CH_2)_{0-4}-(CO)_{0-1}-aryl$;

$-(CH_2)_{0-4}-(CO)_{0-1}-heteroaryl$;

$-(CH_2)_{0-4}-(CO)_{0-1}-heterocycloalkyl$;

20 $-(CH_2)_{0-4}-CO_2R_{215}$;

$-(CH_2)_{0-4}-SO_2-NR_{220}R_{225}$;

$-(CH_2)_{0-4}-S(O)_{0-2}-(C_1-C_8 \text{ alkyl})$;

$-(CH_2)_{0-4}-S(O)_{0-2}-(C_3-C_7 \text{ cycloalkyl})$;

$-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO_2R_{215}$;

25 $-(CH_2)_{0-4}-N(H \text{ or } R_{215})-SO_2-R_{220}$;

$-(CH_2)_{0-4}-N(H \text{ or } R_{215})-CO-N(R_{215})_2$;

$-(CH_2)_{0-4}-N(-H \text{ or } R_{215})-CO-R_{220}$;

$-(CH_2)_{0-4}-NR_{220}R_{225}$;

$-(CH_2)_{0-4}-O-CO-(C_1-C_6 \text{ alkyl})$;

30 $-(CH_2)_{0-4}-O-(R_{215})$;

$-(CH_2)_{0-4}-S-(R_{215})$;

$-(CH_2)_{0-4}-O-(C_1-C_6 \text{ alkyl optionally substituted with 1, 2, 3, or 5 } -F)$;

$-C_2-C_6$ alkenyl optionally substituted with 1 or 2 R_{205}
35 groups;

-C₂-C₆ alkynyl optionally substituted with 1 or 2 R₂₀₅ groups;
and
-(CH₂)₀₋₄- C₃-C₇ cycloalkyl;
5 wherein each aryl group included within R₂₀₀ is optionally substituted with 1, 2, or 3 groups that are independently
-R₂₀₅,
-R₂₁₀ or
-C₁-C₆ alkyl substituted with 1, 2, or 3 groups that
10 are independently R₂₀₅ or R₂₁₀;
wherein each heterocycloalkyl group included within R₂₀₀ is optionally substituted with 1, 2, or 3 groups that are independently R₂₁₀;
wherein each heteroaryl group included within R₂₀₀ is
15 optionally substituted with 1, 2, or 3 groups that are independently
-R₂₀₅,
-R₂₁₀, or
-C₁-C₆ alkyl substituted with 1, 2, or 3 groups that
20 are independently
-R₂₀₅ or
-R₂₁₀;
wherein R₂₀₅ at each occurrence is independently selected from the group
25 consisting of
-C₁-C₆ alkyl,
-C₂-C₆ alkenyl,
-C₂-C₆ alkynyl,
-C₁-C₆ haloalkoxy
30 -(CH₂)₀₋₃(C₃-C₇ cycloalkyl)
-halogen,
-(CH₂)₀₋₆-OH,
-O-phenyl,
-SH,
35 -(CH₂)₀₋₆-C≡N,

- (CH₂)₀₋₆-C(=O)NR₂₃₅R₂₄₀
-CF₃,
-C₁-C₆ alkoxy, and
-NR₂₃₅R₂₄₀,
5 wherein R₂₁₀ at each occurrence is
independently selected from the group
consisting of
-C₁-C₆ alkyl optionally substituted with 1,
2, or 3 R₂₀₅ groups;
10 -C₂-C₆ alkenyl optionally substituted with
1, 2, or 3 R₂₀₅ groups;
-C₂-C₆ alkynyl optionally substituted with
1, 2, or 3 R₂₀₅ groups;
-halogen;
15 -C₁-C₆ alkoxy;
-C₁-C₆ haloalkoxy;
-NR₂₂₀R₂₂₅;
-OH;
-C≡N;
20 -C₃-C₇ cycloalkyl optionally substituted
with 1, 2, or 3 R₂₀₅ groups;
-CO-(C₁-C₄ alkyl);
-SO₂-NR₂₃₅R₂₄₀;
-CO-NR₂₃₅R₂₄₀;
25 -SO₂-(C₁-C₄ alkyl); and
=O; wherein
wherein R₂₁₅ at each occurrence is independently selected
from the group consisting of
-C₁-C₆ alkyl,
30 -(CH₂)₀₋₂-(aryl),
-C₂-C₆ alkenyl,
-C₂-C₆ alkynyl,
-C₃-C₇ cycloalkyl,
-(CH₂)₀₋₂-(heteroaryl), and
35 -(CH₂)₀₋₂-(heterocycloalkyl);

wherein the aryl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 groups that are independently

-R₂₀₅ or

5

-R₂₁₀;

wherein the heterocycloalkyl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 R₂₁₀;

wherein each heteroaryl group included within R₂₁₅ is optionally substituted with 1, 2, or 3 R₂₁₀;

10 wherein R₂₂₀ and R₂₂₅ at each occurrence are independently selected from the group consisting of

-H,

-C₁-C₆ alkyl,

-hydroxy C₁-C₆ alkyl,

15

-amino C₁-C₆ alkyl,

-halo C₁-C₆ alkyl,

-(CH₂)₀₋₂-(C₃-C₇ cycloalkyl),

-(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl),

-C₂-C₆ alkenyl,

20

-C₂-C₆ alkynyl,

-aryl,

-heteroaryl, and

-heterocycloalkyl;

25 wherein the aryl, heteroaryl or heterocycloalkyl group included within R₂₂₀ and R₂₂₅ is optionally substituted with 1, 2, or 3 R₂₇₀ groups,

wherein R₂₇₀ at each occurrence is independently

-R₂₀₅,

30 R₂₀₅ groups;
-C₂-C₆ alkenyl optionally substituted with 1, 2, or 3

R₂₀₅ groups;
-C₂-C₆ alkynyl optionally substituted with 1, 2, or 3

R₂₀₅ groups;
-halogen;

35

-halogen;

-C₁-C₆ alkoxy;
-C₁-C₆ haloalkoxy;
-NR₂₃₅R₂₄₀;
-OH;
5 -C≡N;
-C₃-C₇ cycloalkyl optionally substituted with 1, 2,
or 3 R₂₀₅ groups;
-CO-(C₁-C₄ alkyl);
-SO₂-NR₂₃₅R₂₄₀;
10 -CO-NR₂₃₅R₂₄₀;
-SO₂-(C₁-C₄ alkyl); and
=O;

wherein R₂₃₅ and R₂₄₀ at each occurrence are independently

-H, or
15 -C₁-C₆ alkyl;
-phenyl

wherein R₂₄₅ and R₂₅₀ at each occurrence are independently
selected from the group consisting of

-H,
20 -(CH₂)₀₋₄CO₂C₁-C₄ alkyl
-(CH₂)₀₋₄C(=O)C₁-C₄ alkyl
-C₁-C₄ alkyl,
-C₁-C₄ hydroxyalkyl,
-C₁-C₄ alkoxy,
25 -C₁-C₄ haloalkoxy,
-(CH₂)₀₋₄-C₃-C₇ cycloalkyl,
-C₂-C₆ alkenyl,
-C₂-C₆ alkynyl,
-(CH₂)₀₋₄ aryl,
30 -(CH₂)₀₋₄ heteroaryl, and
-(CH₂)₀₋₄ heterocycloalkyl, or

wherein R₂₄₅ and R₂₅₀ are taken together with the carbon to
which they are attached to form a monocycle or bicycle of
3, 4, 5, 6, 7 or 8 carbon atoms, optionally where 1 or 2

carbon atoms is replaced by a heteroatom selected from the group consisting of

-O-,

-S-,

5 -SO₂-, and

-NR₂₂₀-;

wherein the aryl, heteroaryl or heterocycloalkyl group included within R₂₄₅ and R₂₅₀ is optionally substituted with 1, 2, or 3 groups that are independently halogen, C₁₋₆ alkyl, CN or OH;

10

wherein R₂₅₅ and R₂₆₀ at each occurrence are independently selected from the group consisting of

-H;

-C₁-C₆ alkyl optionally substituted with 1, 2, or 3 R₂₀₅

15 groups;

-(CH₂)₁₋₂-S(O)₀₋₂-(C₁-C₆ alkyl);

-(CH₂)₀₋₄-C₃-C₇ cycloalkyl optionally substituted with 1, 2, or 3 R₂₀₅ groups;

-(CH₂)₀₋₄-aryl;

20

-(CH₂)₀₋₄-heteroaryl;

-(CH₂)₀₋₄-heterocycloalkyl;

wherein each aryl group included within R₂₅₅ and R₂₆₀ is optionally substituted with 1, 2, or 3 groups that are independently

25

-R₂₀₅,

-R₂₁₀, or

-C₁-C₆ alkyl substituted with 1, 2, or 3 groups that are independently

-R₂₀₅ or

30

-R₂₁₀;

where each heteroaryl group included within R₂₅₅ and R₂₆₀ is optionally substituted with 1, 2, 3, or 4 R₂₀₀ groups, and

where each heterocycloalkyl group included within R_{255} and R_{260} is optionally substituted with 1, 2, 3, or 4 R_{210} groups.

The invention also provides methods for the treatment or
5 prevention of Alzheimer's disease, mild cognitive impairment
Down's syndrome, Hereditary Cerebral Hemorrhage with
Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy,
other degenerative dementias, dementias of mixed vascular and
degenerative origin, dementia associated with Parkinson's
10 disease, dementia associated with progressive supranuclear
palsy, dementia associated with cortical basal degeneration,
diffuse Lewy body type of Alzheimer's disease comprising
administration of a therapeutically effective amount of a
compound or salt of formula I, to a patient in need thereof.

15 Preferably, the patient is a human.

More preferably, the disease is Alzheimer's disease.

More preferably, the disease is dementia.

The invention also provides pharmaceutical compositions
comprising a compound or salt of formula I and at least one
20 pharmaceutically acceptable carrier, solvent, adjuvant or
diluent.

The invention also provides the use of a compound or salt
according to formula I for the manufacture of a medicament.

The invention also provides the use of a compound or salt
25 of formula I for the treatment or prevention of Alzheimer's
disease, mild cognitive impairment Down's syndrome, Hereditary
Cerebral Hemorrhage with Amyloidosis of the Dutch-Type,
cerebral amyloid angiopathy, other degenerative dementias,
dementias of mixed vascular and degenerative origin, dementia
30 associated with Parkinson's disease, dementia associated with
progressive supranuclear palsy, dementia associated with
cortical basal degeneration, or diffuse Lewy body type of
Alzheimer's disease.

The invention also provides compounds, pharmaceutical
35 compositions, kits, and methods for inhibiting beta-secretase-

mediated cleavage of amyloid precursor protein (APP). More particularly, the compounds, compositions, and methods of the invention are effective to inhibit the production of A-beta peptide and to treat or prevent any human or veterinary
5 disease or condition associated with a pathological form of A-beta peptide.

The compounds, compositions, and methods of the invention are useful for treating humans who have Alzheimer's Disease (AD), for helping prevent or delay the onset of AD, for
10 treating patients with mild cognitive impairment (MCI), and preventing or delaying the onset of AD in those patients who would otherwise be expected to progress from MCI to AD, for treating Down's syndrome, for treating Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type, for treating
15 cerebral beta-amyloid angiopathy and preventing its potential consequences such as single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, for treating dementia associated with Parkinson's disease, dementia
20 associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, and diffuse Lewy body type AD, and for treating frontotemporal dementias with parkinsonism (FTDP).

The compounds of the invention possess beta-secretase
25 inhibitory activity. The inhibitory activities of the compounds of the invention is readily demonstrated, for example, using one or more of the assays described herein or known in the art.

Unless the substituents for a particular formula are
30 expressly defined for that formula, they are understood to carry the definitions set forth in connection with the preceding formula to which the particular formula makes reference.

The invention also provides methods of preparing the compounds of the invention and the intermediates used in those methods.

5 DETAILED DESCRIPTION OF THE INVENTION

As noted above, the invention provides compounds of formula I.

Preferred compounds of formula I include those of formula I-1, i.e., compounds of formula I wherein X is $-(C=O)-$.

10 Preferred compounds of the formula I and formula I-1 include compounds of the formula I-2, i.e., compounds of the formula I or formula I-1 wherein:

Z is aryl or heteroaryl, wherein each ring is independently optionally substituted with 1 or 2 groups
15 independently selected from halogen, $-OH$, $-OCF_3$, $-O$ -phenyl, $-CN$, $-NR_{100}R_{101}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, $(CH_2)_{0-3}(C_3-C_7$ cycloalkyl), aryl, heteroaryl, or heterocyclyl wherein, the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl,
20 or heterocyclyl groups are optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, halogen, $-OH$, $-CN$, or $-NR_{100}R_{101}$;

25 where R_{100} and R_{101} at each occurrence are independently H, C_1-C_6 alkyl, or phenyl.

Preferred compounds of the formula I-2 also include those wherein:

Z is aryl or heteroaryl, wherein each ring is independently
30 optionally substituted with 1 or 2 groups independently selected from halogen, $-OH$, $-OCF_3$, $-O$ -phenyl, $-CN$, $-NR_{100}R_{101}$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, wherein the alkyl, alkenyl, alkynyl, or alkoxy groups are optionally substituted with
35 1 or 2 substituents independently selected from the

groupconsisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, halogen, -OH, -CN, or -NR₁₀₀R₁₀₁;

5 where R₁₀₀ and R₁₀₁ at each occurrence are independently H, C₁-C₆ alkyl, or phenyl.

Preferred compounds of the formula I-2 also include those wherein:

10 Z is phenyl, pyridinyl, pyrazinyl, pyrazolyl, triazolyl, isoxazolyl, imidazolyl, or thiophenyl, wherein each ring is independently optionally substituted with 1 or 2 groups independently selected from halogen, -OH, -OCF₃, -O-phenyl, -CN, -NR₁₀₀R₁₀₁, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, wherein the alkyl, alkenyl, alkynyl, or alkoxy groups are optionally substituted with
15 1 or 2 substitutents independently selected from the groupconsisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, halogen, -OH, -CN, or -NR₁₀₀R₁₀₁;

20 where R₁₀₀ and R₁₀₁ at each occurrence are independently H, C₁-C₆ alkyl, or phenyl.

Preferred compounds of the formula I, formula I-1, and formula I-2 include compounds of the formula I-3, i.e., compounds of the formula I, formula I-1, or formula I-2 wherein:

25 R₁ is -C₁-C₆ alkyl-aryl, -C₁-C₆ alkyl-heteroaryl, or -C₁-C₆ alkyl-heterocyclyl, wherein each aryl group at each occurrence is optionally substituted with 1, 2 or 3 R₅₀ groups;

30 wherein R₅₀ is independently selected from halogen, OH, SH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, -S(O)₀₋₂-(C₁-C₄ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, or C₃-C₈ cycloalkyl;

35 wherein the alkyl, alkenyl, alkynyl, alkoxy, or cycloalkyl groups are optionally substituted with 1 or 2 substituents independently selected from the

group consisting of C₁-C₄ alkyl, halogen, OH, -NR₅R₆,
CN, C₁-C₄ haloalkoxy, NR₇R₈, and C₁-C₄ alkoxy;

wherein R₅ and R₆ at each occurrence are
independently H or C₁-C₆ alkyl; or

5 wherein R₅ and R₆ and the nitrogen to which
they are attached, at each occurrence form
a 5 or 6 membered heterocycloalkyl ring;
and

10 wherein R₇ and R₈ are independently
selected from the group consisting of H; -
C₁-C₄ alkyl optionally substituted with 1,
2, or 3 groups independently selected from
the group consisting of -OH, -NH₂, and
halogen; -C₃-C₆ cycloalkyl; -(C₁-C₄ alkyl)-
15 O-(C₁-C₄ alkyl); -C₂-C₄ alkenyl; and -C₂-C₄
alkynyl;

wherein each heteroaryl at each occurrence is optionally
substituted with 1 or 2 R₅₀ groups;

20 wherein each heterocycloalkyl group at each occurrence is
optionally substituted with 1 or 2 groups that are
independently R₅₀ or =O.

Preferred compounds of formula I-3 also include those
wherein

25 R₁ is -(CH₂)-aryl, where the aryl is optionally substituted
with 1, 2 or 3 R₅₀ groups;

wherein R₅₀ is independently selected from halogen,
OH, SH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, -S(O)₀₋₂-(C₁-C₄
alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-
C₆ alkoxy, and C₃-C₈ cycloalkyl.

30 Preferred compounds of formula I-3 also include those
wherein

R₁ is -CH₂-phenyl where the phenyl ring is optionally
substituted with 1, 2, or 3 groups independently selected
from halogen, OH, SH, CN, -CO-(C₁-C₄ alkyl), -NR₇R₈, -S(O)₀₋

2-(C₁-C₄ alkyl), C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ alkoxy, and C₃-C₈ cycloalkyl.

Preferred compounds of formula I-3 also include those wherein

- 5 R₁ is -CH₂-phenyl where the phenyl ring is optionally substituted with 1 or 2 groups independently selected from halogen, C₁-C₂ alkyl, C₁-C₂ alkoxy, hydroxy.

Preferred compounds of formula I-3 also include those wherein R₁ is benzyl or 3,5-difluorobenzyl.

- 10 Preferred compounds of the formula I, formula I-1, formula I-2 and formula I-3 include compounds of the formula I-4, i.e., compounds of the formula I, formula I-1, formula I-2, or formula I-3 wherein: R₂ and R₃ are both hydrogen.

- 15 Preferred compounds of the formula I, formula I-1, formula I-2 formula I-3 and formula I-4 include compounds of the formula I-5, i.e., compounds of the formula I, formula I-1, formula I-2, formula I-3, or formula I-4 wherein R₁₅ is hydrogen.

- 20 Preferred compounds of the formula I, formula I-1, formula I-2 formula I-3 formula I-4 and formula I-5 include compounds of the formula I-6, i.e., compounds of the formula I, formula I-1, formula I-2, formula I-3, formula I-4 or formula I-5 wherein:

wherein R_C is selected from the group consisting of:

- 25 -(CH₂)₀₋₃-(C₃-C₈) cycloalkyl wherein cycloalkyl is optionally substituted with 1, 2, or 3 groups independently selected from -R₂₀₅, -CO₂-(C₁-C₄ alkyl) and aryl;
-(CH₂)₀₋₃-aryl;
-(CH₂)₀₋₃-heteroaryl;
30 -(CH₂)₀₋₃-heterocycloalkyl;
-aryl-aryl; and

- a monocyclic or bicyclic ring of 5, 6, 7, 8, 9, or 10 carbons fused to 1 or 2 aryl, heteroaryl, or heterocycloalkyl groups, wherein each aryl, heteroaryl and
35 heterocycloalkyl group is optionally independently

substituted with 1, 2, or 3 R₂₀₀ groups and wherein 1, 2 or 3 carbons of the monocyclic or bicyclic ring is optionally replaced with

-NH, -N(CO)₀₋₁R₂₁₅, -N(CO)₀₋₁R₂₂₀, -O-, or -S(=O)₀₋₂,

5 and wherein the monocyclic or bicyclic ring can be optionally substituted with 1, 2 or 3 groups that are independently -R₂₀₅ -R₂₄₅, R₂₅₀ or =O;

wherein each aryl is optionally substituted with 1, 2, or 3 independently selected R₂₀₀ groups;

10 each heteroaryl is optionally substituted with 1, 2, or 3 independently selected R₂₀₀ groups; and

each heterocycloalkyl is optionally substituted with 1, 2, or 3 independently selected R₂₀₀ groups.

15 Preferred compounds of the formula I-6 include those wherein:

R_C is a monocyclic or bicyclic ring of 5, 6, 7 8, 9, or 10 carbons fused to 1 or 2 aryl, heteroaryl, or heterocycloalkyl groups wherein 1, 2 or 3 carbons of the monocyclic or bicyclic ring is optionally replaced with


20 -NH, -N(CO)₀₋₁R₂₁₅, -N(CO)₀₋₁R₂₂₀, -O, or -S(=O)₀₋₂, and wherein the monocyclic or bicyclic ring can be optionally substituted with 1, 2 or 3 groups that are independently -R₂₀₅ -R₂₄₅, R₂₅₀ or =O.

25 Preferred compounds of the formula I-6 include those wherein:

R_C is a cyclohexyl ring fused to 1 aryl, heteroaryl, or heterocycloalkyl group wherein 1 carbon of the cyclohexyl ring is optionally replaced with -SO₂, or -NH- and wherein the bicyclic ring can be optionally substituted with 1, 2 or 3 groups that are independently -R₂₀₅, -R₂₄₅, R₂₅₀ or =O.

30 Preferred compounds of the formula I-6 also include those wherein:

R_C is



wherein x_1 , x_2 , and x_3 are independently $-\text{CHR}_{245}$, SO_2 , or NH , and wherein the phenyl ring is optionally substituted with 1 or 2 $-\text{R}_{245}$ groups.

5 More preferred compounds of the formula I-6 also include those wherein one of x_1 , x_2 , or x_3 is SO_2 .

More preferred compounds of the formula I-6 also include those wherein one of x_1 , x_2 , or x_3 is NH .

10 More preferred compounds of the formula I-6 also include those wherein x_1 , x_2 , and x_3 are each CH_2 .

In another aspect, the invention provides the intermediates that are useful in the preparation of the compounds of interest.

The invention also provides methods for treating a
15 patient who has, or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of
20 Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar
25 hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy
30 body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically

effective amount of a compound of formula (I) or a pharmaceutically acceptable salts thereof.

In an embodiment, this method of treatment can be used where the disease is Alzheimer's disease.

5 In an embodiment, this method of treatment can help prevent or delay the onset of Alzheimer's disease.

In an embodiment, this method of treatment can be used where the disease is mild cognitive impairment.

10 In an embodiment, this method of treatment can be used where the disease is Down's syndrome.

In an embodiment, this method of treatment can be used where the disease is Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type.

15 In an embodiment, this method of treatment can be used where the disease is cerebral amyloid angiopathy.

In an embodiment, this method of treatment can be used where the disease is degenerative dementias.

20 In an embodiment, this method of treatment can be used where the disease is diffuse Lewy body type of Alzheimer's disease.

In an embodiment, this method of treatment can treat an existing disease.

In an embodiment, this method of treatment can prevent a disease from developing.

25 In an embodiment, this method of treatment can employ therapeutically effective amounts: for oral administration from about 0.1 mg/day to about 1,000 mg/day; for parenteral, sublingual, intranasal, intrathecal administration from about 0.5 to about 100 mg/day; for depo administration and implants
30 from about 0.5 mg/day to about 50 mg/day; for topical administration from about 0.5 mg/day to about 200 mg/day; for rectal administration from about 0.5 mg to about 500 mg.

In an embodiment, this method of treatment can employ therapeutically effective amounts: for oral administration

from about 1 mg/day to about 100 mg/day; and for parenteral administration from about 5 to about 50 mg daily.

In an embodiment, this method of treatment can employ therapeutically effective amounts for oral administration from
5 about 5 mg/day to about 50 mg/day.

The invention also includes pharmaceutical compositions which include a compound of formula (I) or a pharmaceutically acceptable salts thereof.

The invention also includes the use of a compound of
10 formula (I) or pharmaceutically acceptable salts thereof for the manufacture of a medicament for use in treating a patient who has, or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's
15 disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-
20 Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia
25 associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment.

In an embodiment, this use of a compound of formula (I)
30 can be employed where the disease is Alzheimer's disease.

In an embodiment, this use of a compound of formula (I) can help prevent or delay the onset of Alzheimer's disease.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is mild cognitive
35 impairment.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is Down's syndrome.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is cerebral amyloid angiopathy.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is degenerative dementias.

In an embodiment, this use of a compound of formula (I) can be employed where the disease is diffuse Lewy body type of Alzheimer's disease.

In an embodiment, this use of a compound employs a pharmaceutically acceptable salt selected from the group consisting of salts of the following acids hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, citric, methanesulfonic, $\text{CH}_3-(\text{CH}_2)_n-\text{COOH}$ where n is 0 thru 4, $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$ where n is as defined above, $\text{HOOC}-\text{CH}=\text{CH}-\text{COOH}$, and phenyl-COOH.

The invention also includes methods for inhibiting beta-secretase activity, for inhibiting cleavage of amyloid precursor protein (APP), in a reaction mixture, at a site between Met596 and Asp597, numbered for the APP-695 amino acid isotype, or at a corresponding site of an isotype or mutant thereof; for inhibiting production of amyloid beta peptide (A beta) in a cell; for inhibiting the production of beta-amyloid plaque in an animal; and for treating or preventing a disease characterized by beta-amyloid deposits in the brain. These methods each include administration of a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salts thereof.

The invention also includes a method for inhibiting beta-secretase activity, including exposing said beta-secretase to

an effective inhibitory amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

5 In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of less than 50 micromolar.

In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 10 micromolar or less.

10 In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 1 micromolar or less.

In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 10 nanomolar or less.

15 In an embodiment, this method includes exposing said beta-secretase to said compound *in vitro*.

In an embodiment, this method includes exposing said beta-secretase to said compound in a cell.

20 In an embodiment, this method includes exposing said beta-secretase to said compound in a cell in an animal.

In an embodiment, this method includes exposing said beta-secretase to said compound in a human.

25 The invention also includes a method for inhibiting cleavage of amyloid precursor protein (APP), in a reaction mixture, at a site between Met596 and Asp597, numbered for the APP-695 amino acid isotype; or at a corresponding site of an isotype or mutant thereof, including exposing said reaction mixture to an effective inhibitory amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

30 In an embodiment, this method employs a cleavage site: between Met652 and Asp653, numbered for the APP-751 isotype; between Met 671 and Asp 672, numbered for the APP-770 isotype; between Leu596 and Asp597 of the APP-695 Swedish Mutation; between Leu652 and Asp653 of the APP-751 Swedish Mutation; or
35 between Leu671 and Asp672 of the APP-770 Swedish Mutation.

In an embodiment, this method exposes said reaction mixture *in vitro*.

In an embodiment, this method exposes said reaction mixture in a cell.

5 In an embodiment, this method exposes said reaction mixture in an animal cell.

In an embodiment, this method exposes said reaction mixture in a human cell.

10 The invention also includes a method for inhibiting production of amyloid beta peptide (A beta) in a cell, including administering to said cell an effective inhibitory amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

15 In an embodiment, this method includes administering to an animal.

In an embodiment, this method includes administering to a human.

20 The invention also includes a method for inhibiting the production of beta-amyloid plaque in an animal, including administering to said animal an effective inhibitory amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

In an embodiment, this method includes administering to a human.

25 The invention also includes a method for treating or preventing a disease characterized by beta-amyloid deposits in the brain including administering to a patient an effective therapeutic amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

30 In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of less than 50 micromolar.

35 In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 10 micromolar or less.

In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 1 micromolar or less.

5 In an embodiment, this method employs a compound that inhibits 50% of the enzyme's activity at a concentration of 10 nanomolar or less.

In an embodiment, this method employs a compound at a therapeutic amount in the range of from about 0.1 to about 1000 mg/day.

10 In an embodiment, this method employs a compound at a therapeutic amount in the range of from about 15 to about 1500 mg/day.

In an embodiment, this method employs a compound at a therapeutic amount in the range of from about 1 to about 100
15 mg/day.

In an embodiment, this method employs a compound at a therapeutic amount in the range of from about 5 to about 50 mg/day.

In an embodiment, this method can be used where said
20 disease is Alzheimer's disease.

In an embodiment, this method can be used where said disease is Mild Cognitive Impairment, Down's Syndrome, or Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type.

25 The invention also includes a composition including beta-secretase complexed with a compound of formula (I), or a pharmaceutically acceptable salt thereof.

The invention also includes a method for producing a beta-secretase complex including exposing beta-secretase to a
30 compound of formula (I), or a pharmaceutically acceptable salt thereof, in a reaction mixture under conditions suitable for the production of said complex.

In an embodiment, this method employs exposing *in vitro*.

In an embodiment, this method employs a reaction mixture
35 that is a cell.

The invention also includes a component kit including component parts capable of being assembled, in which at least one component part includes a compound of formula I enclosed in a container.

5 In an embodiment, this component kit includes lyophilized compound, and at least one further component part includes a diluent.

10 The invention also includes a container kit including a plurality of containers, each container including one or more unit dose of a compound of formula (I):, or a pharmaceutically acceptable salt thereof.

 In an embodiment, this container kit includes each container adapted for oral delivery and includes a tablet, gel, or capsule.

15 In an embodiment, this container kit includes each container adapted for parenteral delivery and includes a depot product, syringe, ampoule, or vial.

20 In an embodiment, this container kit includes each container adapted for topical delivery and includes a patch, medipad, ointment, or cream.

 The invention also includes an agent kit including a compound of formula (I), or a pharmaceutically acceptable salt thereof; and one or more therapeutic agent selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, an A beta peptide, and an anti-A beta antibody.

30 The invention also includes a composition including a compound of formula (I), or a pharmaceutically acceptable salt thereof; and an inert diluent or edible carrier.

 In an embodiment, this composition includes a carrier that is an oil.

 The invention also includes a composition including: a compound of formula (I), or a pharmaceutically acceptable salt


thereof; and a binder, excipient, disintegrating agent, lubricant, or gildant.

The invention also includes a composition including a compound of formula (I), or a pharmaceutically acceptable salt thereof; disposed in a cream, ointment, or patch.

The invention provides compounds of formula (I) that are useful in treating and preventing Alzheimer's disease. The compounds of the invention can be prepared by one skilled in the art based only on knowledge of the compound's chemical structure. The chemistry for the preparation of the compounds of this invention is known to those skilled in the art. In fact, there is more than one process to prepare the compounds of the invention. Specific examples of methods of preparation can be found in the art.

An example of one of many various processes that can be used to prepare the compounds of the invention is set forth in Scheme I.

SCHEME I




The epoxide opening in the first step in Scheme I is carried out with a 1:1 to 1:5 ratio of the erythro epoxide and C-terminal $\text{R}-\text{NH}_2$ piece. 1-6 Equivalents of a tertiary amine base (such as diisopropylethylamine or triethylamine) are then added, followed by 10 mL/mmol alcoholic solvent, such as

methanol or isopropanol. This reaction is run at room temperature to 110 °C for a time until reaction is deemed complete, between 0.5-16 hr. Upon completion, the reaction mixture is concentrated under reduced pressure, or by overflow of inert gas.

The BOC-group deprotection in the second step is accomplished by using 3-5 equivalents of acid, such as hydrogen chloride or trifluoroacetic acid in appropriate solvent, such as dioxane, diethyl ether, or methylene chloride, with respect to the amount of starting material. This reaction is run at room temperature to 100 °C for 0.5-16 hr, until reaction is deemed complete. The solvent is then removed under reduced pressure, or by overflow of inert gas.

The starting amine in the final step is placed with 2-4 equiv tertiary amine base, such as triethylamine or diisopropylethylamine. Then, 1.1 equiv of the R'-COOH carboxylic acid is added. The starting reagents are then dissolved in 2 ml/mmol of appropriate polar aprotic solvent, such as THF or DMF. Finally, 1.1 equiv of coupling reagent, such as HBTU, dissolved in an appropriate amount of solvent, is added. Each reaction is run for 0.5-16 hr at anywhere between room temperature and 100 °C, until LC/MS analysis indicates reaction is complete. Final purification is achieved using preparative HPLC.

SCHEME II



Scheme II illustrates the preparation of compounds using the readily obtainable 6-iodo-chroman-4-ol (1) as a starting material (see *Synthesis*, **1997**, 23-25). One skilled in the art will recognize that there are several methods for the conversion of the alcohol functionality to the desired amino compounds of formula (2). In Scheme II the alcohol (1) is first activated with methane sulfonyl chloride and the resulting mesylate displaced with sodium azide NaN₃. Alternative methods for the conversion of an alcohol to an azide are well known to one skilled in the art. The resulting azide is subsequently reduced using trimethylphosphine in a mixture of THF and water. One skilled in the art will recognize that there are several methods for the reduction of an azide to the corresponding amine. For examples, see Larock, R.C. in *Comprehensive Organic Transformations*, Wiley-VCH Publishers, 1999. This reduction of the azide produces a mixture of enantiomers of the amine (2). This enantiomeric mixture can be separated by means known to those skilled in

the art such as low temperature recrystallization of a chiral salt or by chiral preparative HPLC , most preferably by HPLC, employing commercially available chiral columns.

The resulting amine (2) is used to open the epoxide (3) to afford the protected (6-iodo-3,4-dihydro-2H-chromen-4-yl)amino propyl carbamate (4). Suitable reaction conditions for opening the epoxide (3) include running the reaction in a wide range of common and inert solvents. C₁-C₆ alcohol solvents are preferred and isopropyl alcohol most preferred. The reactions can be run at temperatures ranging from 20-25 °C up to the reflux temperature of the alcohol employed. The preferred temperature range for conducting the reaction is between 50°C and the refluxing temperature of the alcohol employed.


The protected iodo-chromen (4) is deprotected to the corresponding amine by means known to those skilled in the art for removal of amine protecting groups. Suitable means for removal of the amine protecting group depend on the nature of the protecting group. Those skilled in the art, knowing the nature of a specific protecting group, know which reagent is preferable for its removal. For example, it is preferred to remove the preferred protecting group, BOC, by dissolving the protected iodo-chroman in a trifluoroacetic acid/dichloromethane (1/1) mixture. When complete the solvents are removed under reduced pressure to give the corresponding amine (as the corresponding salt, i.e. trifluoroacetic acid salt) which is used without further purification. However, if desired, the amine can be purified further by means well known to those skilled in the art, such as for example recrystallization. Further, if the non-salt form is desired that also can be obtained by means known to those skilled in the art, such as for example, preparing the free base amine via treatment of the salt with mild basic conditions. Additional BOC deprotection conditions and deprotection conditions for other protecting groups can be found in T. W.

Green and P. G. M. Wuts in *Protecting Groups in Organic Chemistry*, John Wiley and Sons, 1999.

The amine is then reacted with an appropriately substituted amide forming agent Z-(CO)-Y to produce coupled amides (5) by nitrogen acylation means known to those skilled in the art. Nitrogen acylation conditions for the reaction of amine with an amide forming agent Z-(CO)-Y are known to those skilled in the art and can be found in R.C. Larock in *Comprehensive Organic Transformations*, VCH Publishers, 1989, p. 981, 979, and 972. Y comprises -OH (carboxylic acid) or halide (acyl halide), preferably chlorine, imidazole (acyl imidazole), or a suitable group to produce a mixed anhydride.

The acylated iodo-chromen (5) is coupled with an appropriately functionalized organometallic $R_{200}M$ to afford compounds of formula (6) using conditions known to those skilled in the art. One skilled in the art will recognize that there are several methods for coupling various alkyl and aryl groups to an aromatic iodide. For examples, see L. S. Hegedus *Transition Metals in the Synthesis of Complex Organic Molecules*, University Science, 1999.

SCHEME III



Amines of formula (8) can be prepared by coupling the appropriately functionalized organometallic to 6-iodo-chroman-4-ol (1) or to the appropriately protected iodo-amino chroman of the formula (7), as shown in Scheme III. The chemistry from this point forward follows the generalizations described for Scheme II.

The protection of amines is conducted, where appropriate, by methods known to those skilled in the art. Amino protecting groups are known to those skilled in the art. See for example, "Protecting Groups in Organic Synthesis", John Wiley and sons, New York, N.Y., 1981, Chapter 7; "Protecting Groups in Organic Chemistry", Plenum Press, New York, N.Y., 1973, Chapter 2. When the amino protecting group is no longer needed, it is removed by methods known to those skilled in the art. By definition the amino protecting group must be readily removable. A variety of suitable methodologies are known to those skilled in the art; see also T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry, John Wiley and Sons, 1991. Suitable amino protecting groups include t-butoxycarbonyl, benzyl-oxycarbonyl, formyl, trityl, phthalimido, trichloro-acetyl, chloroacetyl, bromoacetyl, iodoacetyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-ethoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, 2-(4-xenyl)isopropoxycarbonyl, 1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl, 2-phenylprop-2-yloxycarbonyl, 2-(p-toluy)prop-2-yloxy-carbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl, cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycabonyl, 2-methylcyclohexanyloxycarbonyl, 2-(4-toluylsulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)-ethoxycarbonyl, 2-(triphenylphosphino)ethoxycarbonyl,

fluorenylmethoxycarbonyl, 2-(trimethylsilyl)ethoxy-carbonyl,
allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-
enyloxycarbonyl, 5-benzisoxalylmethoxycarbonyl, 4-
acetoxybenzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-
5 ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, 4-
(decyloxy)benzyloxycarbonyl, isobornyloxycarbonyl, 1-
piperidyloxycarbonyl, 9-fluorenylmethyl carbonate, $-CH-CH=CH_2$
and phenyl-C(=N)-H.

It is preferred that the protecting group be *t*-
10 butoxycarbonyl (BOC) and/or benzyloxycarbonyl (CBZ), it is
more preferred that the protecting group be *t*-butoxycarbonyl.
One skilled in the art will recognize suitable methods of
introducing a *t*-butoxycarbonyl or benzyloxycarbonyl protecting
group and may additionally consult T.W. Green and P.G.M. Wuts
15 in "Protective Groups in Organic Chemistry, John Wiley and
Sons, 1991 for guidance.

The compounds of the invention may contain geometric or
optical isomers as tautomers. Thus, the invention includes
all tautomers and pure geometric isomers, such as the *E* and *Z*
20 geometric isomers, as mixtures thereof. Further, the
invention includes pure enantiomers and diastereomers as
mixtures thereof, including racemic mixtures. The individual
geometric isomers, enantiomers or diastereomers may be
prepared or isolated by methods known to those skilled in the
25 art, including but not limited to chiral chromatography;
preparing diastereomers, separating the diastereomers and then
converting the diastereomers into enantiomers through methods
well known in the art.

Compounds of the invention with designated
30 stereochemistry can be included in mixtures, including racemic
mixtures, with other enantiomers, diastereomers, geometric
isomers or tautomers. In a preferred aspect, compounds of the
invention are typically present in these mixtures in
diastereomeric and/or enantiomeric excess of at least 50
35 percent. Preferably, compounds of the invention are present

in these mixtures in diastereomeric and/or enantiomeric excess of at least 80 percent. More preferably, compounds of the invention with the desired stereochemistry are present in diastereomeric and/or enantiomeric excess of at least 90 percent. Even more preferably, compounds of the invention with the desired stereochemistry are present in diastereomeric and/or enantiomeric excess of at least 99 percent.

Several of the compounds of formula (I) are amines, and as such form salts when reacted with acids. Pharmaceutically acceptable salts are preferred over the corresponding amines of formula (I) since they produce compounds which are more water soluble, stable and/or more crystalline. Pharmaceutically acceptable salts are any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered. Pharmaceutically acceptable salts include salts of both inorganic and organic acids. The preferred pharmaceutically acceptable salts include salts of the following acids acetic, aspartic, benzenesulfonic, benzoic, bicarbonic, bisulfuric, bitartaric, butyric, calcium edetate, camsylic, carbonic, chlorobenzoic, citric, edetic, edisylic, estolic, esyl, esylic, formic, fumaric, gluceptic, gluconic, glutamic, glycollylarsanilic, hexamic, hexylresorcinoic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxynaphthoic, isethionic, lactic, lactobionic, maleic, malic, malonic, mandelic, methanesulfonic, methylnitric, methylsulfuric, mucic, muconic, napsylic, nitric, oxalic, p-nitromethanesulfonic, pamoic, pantothenic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic and toluenesulfonic. For other acceptable salts, see *Int. J. Pharm.*, 33, 201-217 (1986) and *J. Pharm. Sci.*, 66(1), 1, (1977).

The invention provides compounds, compositions, kits, and methods for inhibiting beta-secretase enzyme activity and A beta peptide production. Inhibition of beta-secretase enzyme activity halts or reduces the production of A beta from APP
5 and reduces or eliminates the formation of beta-amyloid deposits in the brain.

Methods of the Invention

The compounds of the invention, and pharmaceutically acceptable salts thereof, are useful for treating humans or
10 animals suffering from a condition characterized by a pathological form of beta-amyloid peptide, such as beta-amyloid plaques, and for helping to prevent or delay the onset of such a condition. For example, the compounds are useful for treating Alzheimer's disease, for helping prevent or delay
15 the onset of Alzheimer's disease, for treating patients with MCI (mild cognitive impairment) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of
20 the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's
25 disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, and diffuse Lewy body type Alzheimer's disease. The compounds and compositions of the invention are particularly useful for treating or preventing Alzheimer's disease. When treating or
30 preventing these diseases, the compounds of the invention can either be used individually or in combination, as is best for the patient.

As used herein, the term "treating" means that the compounds of the invention can be used in humans with at least
35 a tentative diagnosis of disease. The compounds of the

invention will delay or slow the progression of the disease thereby giving the individual a more useful life span.

5 The term "preventing" means that the compounds of the invention are useful when administered to a patient who has not been diagnosed as possibly having the disease at the time of administration, but who would normally be expected to develop the disease or be at increased risk for the disease. The compounds of the invention will slow the development of disease symptoms, delay the onset of the disease, or prevent
10 the individual from developing the disease at all. Preventing also includes administration of the compounds of the invention to those individuals thought to be predisposed to the disease due to age, familial history, genetic or chromosomal abnormalities, and/or due to the presence of one or more
15 biological markers for the disease, such as a known genetic mutation of APP or APP cleavage products in brain tissues or fluids.

In treating or preventing the above diseases, the compounds of the invention are administered in a
20 therapeutically effective amount. The therapeutically effective amount will vary depending on the particular compound used and the route of administration, as is known to those skilled in the art.

In treating a patient displaying any of the diagnosed
25 above conditions a physician may administer a compound of the invention immediately and continue administration indefinitely, as needed. In treating patients who are not diagnosed as having Alzheimer's disease, but who are believed to be at substantial risk for Alzheimer's disease, the
30 physician should preferably start treatment when the patient first experiences early pre-Alzheimer's symptoms such as, memory or cognitive problems associated with aging. In addition, there are some patients who may be determined to be at risk for developing Alzheimer's through the detection of a
35 genetic marker such as APOE4 or other biological indicators

that are predictive for Alzheimer's disease. In these situations, even though the patient does not have symptoms of the disease, administration of the compounds of the invention may be started before symptoms appear, and treatment may be continued indefinitely to prevent or delay the onset of the disease.

Dosage Forms and Amounts

The compounds of the invention can be administered orally, parenterally, (IV, IM, depo-IM, SQ, and depo SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally. Dosage forms known to those of skill in the art are suitable for delivery of the compounds of the invention.

Compositions are provided that contain therapeutically effective amounts of the compounds of the invention. The compounds are preferably formulated into suitable pharmaceutical preparations such as tablets, capsules, or elixirs for oral administration or in sterile solutions or suspensions for parenteral administration. Typically the compounds described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art.

About 1 to 500 mg of a compound or mixture of compounds of the invention or a physiologically acceptable salt or ester is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in those compositions or preparations is such that a suitable dosage in the range indicated is obtained. The compositions are preferably formulated in a unit dosage form, each dosage containing from about 2 to about 100 mg, more preferably about 10 to about 30 mg of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each

unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

To prepare compositions, one or more compounds of the invention are mixed with a suitable pharmaceutically acceptable carrier. Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion, or the like. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for lessening or ameliorating at least one symptom of the disease, disorder, or condition treated and may be empirically determined.

Pharmaceutical carriers or vehicles suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration. In addition, the active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, or have another action. The compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.

Where the compounds exhibit insufficient solubility, methods for solubilizing may be used. Such methods are known and include, but are not limited to, using cosolvents such as dimethylsulfoxide (DMSO), using surfactants such as Tween®, and dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts or prodrugs may also be used in formulating effective pharmaceutical compositions.

The concentration of the compound is effective for delivery of an amount upon administration that lessens or ameliorates at least one symptom of the disorder for which the compound is administered. Typically, the compositions are
5 formulated for single dosage administration.

The compounds of the invention may be prepared with carriers that protect them against rapid elimination from the body, such as time-release formulations or coatings. Such carriers include controlled release formulations, such as, but
10 not limited to, microencapsulated delivery systems. The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective
15 concentration may be determined empirically by testing the compounds in known *in vitro* and *in vivo* model systems for the treated disorder.

The compounds and compositions of the invention can be enclosed in multiple or single dose containers. The enclosed
20 compounds and compositions can be provided in kits, for example, including component parts that can be assembled for use. For example, a compound inhibitor in lyophilized form and a suitable diluent may be provided as separated components for combination prior to use. A kit may include a compound
25 inhibitor and a second therapeutic agent for co-administration. The inhibitor and second therapeutic agent may be provided as separate component parts. A kit may include a plurality of containers, each container holding one or more unit dose of the compound of the invention. The
30 containers are preferably adapted for the desired mode of administration, including, but not limited to tablets, gel capsules, sustained-release capsules, and the like for oral administration; depot products, pre-filled syringes, ampoules, vials, and the like for parenteral administration; and

patches, medipads, creams, and the like for topical administration.

5 The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.

10 The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from *in vivo* or *in vitro* test data. It is to be noted that concentrations and dosage
15 values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or
20 supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

25 If oral administration is desired, the compound should be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in
30 combination with an antacid or other such ingredient.

Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules. For the purpose of oral therapeutic administration, the active compound or compounds
35 can be incorporated with excipients and used in the form of

tablets, capsules, or troches. Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.

5 The tablets, pills, capsules, troches, and the like can contain any of the following ingredients or compounds of a similar nature: a binder such as, but not limited to, gum tragacanth, acacia, corn starch, or gelatin; an excipient such as microcrystalline cellulose, starch, or lactose; a disintegrating agent such as, but not limited to, alginic acid
10 and corn starch; a lubricant such as, but not limited to, magnesium stearate; a gildant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate, or fruit flavoring.

15 When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials, which modify the physical form of the dosage unit, for example, coatings of sugar and
20 other enteric agents. The compounds can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings, and flavors.

25 The active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action.

Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include
30 any of the following components: a sterile diluent such as water for injection, saline solution, fixed oil, a naturally occurring vegetable oil such as sesame oil, coconut oil, peanut oil, cottonseed oil, and the like, or a synthetic fatty vehicle such as ethyl oleate, and the like, polyethylene
35 glycol, glycerine, propylene glycol, or other synthetic

solvent; antimicrobial agents such as benzyl alcohol and methyl parabens; antioxidants such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates, and phosphates; and agents for the adjustment of tonicity such as sodium chloride and dextrose. Parenteral preparations can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass, plastic, or other suitable material. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Where administered intravenously, suitable carriers include physiological saline, phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, polypropyleneglycol, and mixtures thereof. Liposomal suspensions including tissue-targeted liposomes may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known for example, as described in U.S. Patent No. 4,522,811.

The active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time-release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid, and the like. Methods for preparation of such formulations are known to those skilled in the art.

The compounds of the invention can be administered orally, parenterally (IV, IM, depo-IM, SQ, and depo-SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally. Dosage forms known to those skilled in the art are suitable for delivery of the compounds of the invention.

Compounds of the invention may be administered enterally or parenterally. When administered orally, compounds of the invention can be administered in usual dosage forms for oral administration as is well known to those skilled in the art.

5 These dosage forms include the usual solid unit dosage forms of tablets and capsules as well as liquid dosage forms such as solutions, suspensions, and elixirs. When the solid dosage forms are used, it is preferred that they be of the sustained release type so that the compounds of the invention need to be

10 administered only once or twice daily.

The oral dosage forms are administered to the patient 1, 2, 3, or 4 times daily. It is preferred that the compounds of the invention be administered either three or fewer times, more preferably once or twice daily. Hence, it is preferred

15 that the compounds of the invention be administered in oral dosage form. It is preferred that whatever oral dosage form is used, that it be designed so as to protect the compounds of the invention from the acidic environment of the stomach. Enteric coated tablets are well known to those skilled in the

20 art. In addition, capsules filled with small spheres each coated to protect from the acidic stomach, are also well known to those skilled in the art.

When administered orally, an administered amount therapeutically effective to inhibit beta-secretase activity,

25 to inhibit A beta production, to inhibit A beta deposition, or to treat or prevent AD is from about 0.1 mg/day to about 1,000 mg/day. It is preferred that the oral dosage is from about 1 mg/day to about 100 mg/day. It is more preferred that the oral dosage is from about 5 mg/day to about 50 mg/day. It is

30 understood that while a patient may be started at one dose, that dose may be varied over time as the patient's condition changes.

Compounds of the invention may also be advantageously delivered in a nano crystal dispersion formulation.

35 Preparation of such formulations is described, for example, in

U.S. Patent 5,145,684. Nano crystalline dispersions of HIV protease inhibitors and their method of use are described in U.S. Patent No. 6,045,829. The nano crystalline formulations typically afford greater bioavailability of drug compounds.

5 The compounds of the invention can be administered parenterally, for example, by IV, IM, depo-IM, SC, or depo-SC. When administered parenterally, a therapeutically effective amount of about 0.5 to about 100 mg/day, preferably from about 5 to about 50 mg daily should be delivered. When a depot
10 formulation is used for injection once a month or once every two weeks, the dose should be about 0.5 mg/day to about 50 mg/day, or a monthly dose of from about 15 mg to about 1,500 mg. In part because of the forgetfulness of the patients with Alzheimer's disease, it is preferred that the parenteral
15 dosage form be a depo formulation.

 The compounds of the invention can be administered sublingually. When given sublingually, the compounds of the invention should be given one to four times daily in the amounts described above for IM administration.

20 The compounds of the invention can be administered intranasally. When given by this route, the appropriate dosage forms are a nasal spray or dry powder, as is known to those skilled in the art. The dosage of the compounds of the invention for intranasal administration is the amount
25 described above for IM administration.

 The compounds of the invention can be administered intrathecally. When given by this route the appropriate dosage form can be a parenteral dosage form as is known to those skilled in the art. The dosage of the compounds of the
30 invention for intrathecal administration is the amount described above for IM administration.

 The compounds of the invention can be administered topically. When given by this route, the appropriate dosage form is a cream, ointment, or patch. Because of the amount of
35 the compounds of the invention to be administered, the patch

is preferred. When administered topically, the dosage is from about 0.5 mg/day to about 200 mg/day. Because the amount that can be delivered by a patch is limited, two or more patches may be used. The number and size of the patch is not
5 important, what is important is that a therapeutically effective amount of the compounds of the invention be delivered as is known to those skilled in the art. The compounds of the invention can be administered rectally by suppository as is known to those skilled in the art. When
10 administered by suppository, the therapeutically effective amount is from about 0.5 mg to about 500 mg.

The compounds of the invention can be administered by implants as is known to those skilled in the art. When administering a compound of the invention by implant, the
15 therapeutically effective amount is the amount described above for depot administration.

Given a particular compound of the invention and a desired dosage form, one skilled in the art would know how to prepare and administer the appropriate dosage form.

20 The compounds of the invention are used in the same manner, by the same routes of administration, using the same pharmaceutical dosage forms, and at the same dosing schedule as described above, for preventing disease or treating patients with MCI (mild cognitive impairment) and preventing
25 or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating or preventing Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its
30 potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia

associated with cortical basal degeneration, and diffuse Lewy body type of Alzheimer's disease.

The compounds of the invention can be used in combination, with each other or with other therapeutic agents or approaches used to treat or prevent the conditions listed above. Such agents or approaches include: acetylcholine esterase inhibitors such as tacrine (tetrahydroaminoacridine, marketed as COGNEX®), donepezil hydrochloride, (marketed as Aricept® and rivastigmine (marketed as Exelon®); gamma-secretase inhibitors; anti-inflammatory agents such as cyclooxygenase II inhibitors; anti-oxidants such as Vitamin E and ginkgolides; immunological approaches, such as, for example, immunization with A beta peptide or administration of anti-A beta peptide antibodies; statins; and direct or indirect neurotropic agents such as Cerebrolysin®, AIT-082 (Emilieu, 2000, *Arch. Neurol.* 57:454), and other neurotropic agents of the future.

In addition, the compounds of formula (I) can also be used with inhibitors of P-glycoprotein (P-gp). P-gp inhibitors and the use of such compounds are known to those skilled in the art. See for example, *Cancer Research*, 53, 4595-4602 (1993), *Clin. Cancer Res.*, 2, 7-12 (1996), *Cancer Research*, 56, 4171-4179 (1996), International Publications WO99/64001 and WO01/10387. The important thing is that the blood level of the P-gp inhibitor be such that it exerts its effect in inhibiting P-gp from decreasing brain blood levels of the compounds of formula (A). To that end the P-gp inhibitor and the compounds of formula (A) can be administered at the same time, by the same or different route of administration, or at different times. The important thing is not the time of administration but having an effective blood level of the P-gp inhibitor.

Suitable P-gp inhibitors include cyclosporin A, verapamil, tamoxifen, quinidine, Vitamin E-TGPS, ritonavir, megestrol acetate, progesterone, rapamycin, 10,11-

methanodibenzosuberane, phenothiazines, acridine derivatives such as GF120918, FK506, VX-710, LY335979, PSC-833, GF-102,918 and other steroids. It is to be understood that additional agents will be found that have the same function and therefore
5 achieve the same outcome; such compounds are also considered to be useful.

The P-gp inhibitors can be administered orally, parenterally, (IV, IM, IM-depo, SQ, SQ-depo), topically, sublingually, rectally, intranasally, intrathecally and by
10 implant.

The therapeutically effective amount of the P-gp inhibitors is from about 0.1 to about 300 mg/kg/day, preferably about 0.1 to about 150 mg/kg daily. It is understood that while a patient may be started on one dose,
15 that dose may have to be varied over time as the patient's condition changes.

When administered orally, the P-gp inhibitors can be administered in usual dosage forms for oral administration as is known to those skilled in the art. These dosage forms
20 include the usual solid unit dosage forms of tablets and capsules as well as liquid dosage forms such as solutions, suspensions and elixirs. When the solid dosage forms are used, it is preferred that they be of the sustained release type so that the P-gp inhibitors need to be administered only
25 once or twice daily. The oral dosage forms are administered to the patient one thru four times daily. It is preferred that the P-gp inhibitors be administered either three or fewer times a day, more preferably once or twice daily. Hence, it is preferred that the P-gp inhibitors be administered in solid
30 dosage form and further it is preferred that the solid dosage form be a sustained release form which permits once or twice daily dosing. It is preferred that what ever dosage form is used, that it be designed so as to protect the P-gp inhibitors from the acidic environment of the stomach. Enteric coated
35 tablets are well known to those skilled in the art. In

addition, capsules filled with small spheres each coated to protect from the acidic stomach, are also well known to those skilled in the art.

5 In addition, the P-gp inhibitors can be administered parenterally. When administered parenterally they can be administered IV, IM, depo-IM, SQ or depo-SQ.

10 The P-gp inhibitors can be given sublingually. When given sublingually, the P-gp inhibitors should be given one thru four times daily in the same amount as for IM administration.

The P-gp inhibitors can be given intranasally. When given by this route of administration, the appropriate dosage forms are a nasal spray or dry powder as is known to those skilled in the art. The dosage of the P-gp inhibitors for
15 intranasal administration is the same as for IM administration.

The P-gp inhibitors can be given intrathecally. When given by this route of administration the appropriate dosage form can be a parenteral dosage form as is known to those
20 skilled in the art.

The P-gp inhibitors can be given topically. When given by this route of administration, the appropriate dosage form is a cream, ointment or patch. Because of the amount of the P-gp inhibitors needed to be administered the patch is
25 preferred. However, the amount that can be delivered by a patch is limited. Therefore, two or more patches may be required. The number and size of the patch is not important, what is important is that a therapeutically effective amount of the P-gp inhibitors be delivered as is known to those
30 skilled in the art.

The P-gp inhibitors can be administered rectally by suppository as is known to those skilled in the art.

The P-gp inhibitors can be administered by implants as is known to those skilled in the art.

There is nothing novel about the route of administration nor the dosage forms for administering the P-gp inhibitors. Given a particular P-gp inhibitor, and a desired dosage form, one skilled in the art would know how to prepare the appropriate dosage form for the P-gp inhibitor.

It should be apparent to one skilled in the art that the exact dosage and frequency of administration will depend on the particular compounds of the invention administered, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, and other medication the individual may be taking as is well known to administering physicians who are skilled in this art.

Inhibition of APP Cleavage

The compounds of the invention inhibit cleavage of APP between Met595 and Asp596 numbered for the APP695 isoform, or a mutant thereof, or at a corresponding site of a different isoform, such as APP751 or APP770, or a mutant thereof (sometimes referred to as the "beta secretase site"). While not wishing to be bound by a particular theory, inhibition of beta-secretase activity is thought to inhibit production of beta amyloid peptide (A beta). Inhibitory activity is demonstrated in one of a variety of inhibition assays, whereby cleavage of an APP substrate in the presence of a beta-secretase enzyme is analyzed in the presence of the inhibitory compound, under conditions normally sufficient to result in cleavage at the beta-secretase cleavage site. Reduction of APP cleavage at the beta-secretase cleavage site compared with an untreated or inactive control is correlated with inhibitory activity. Assay systems that can be used to demonstrate efficacy of the compound inhibitors of the invention are known. Representative assay systems are described, for example, in U.S. Patents No. 5,942,400, 5,744,346, as well as in the Examples below.

The enzymatic activity of beta-secretase and the production of A beta can be analyzed *in vitro* or *in vivo*, using natural, mutated, and/or synthetic APP substrates, natural, mutated, and/or synthetic enzyme, and the test
5 compound. The analysis may involve primary or secondary cells expressing native, mutant, and/or synthetic APP and enzyme, animal models expressing native APP and enzyme, or may utilize transgenic animal models expressing the substrate and enzyme. Detection of enzymatic activity can be by analysis of one or
10 more of the cleavage products, for example, by immunoassay, fluorometric or chromogenic assay, HPLC, or other means of detection. Inhibitory compounds are determined as those having the ability to decrease the amount of beta-secretase cleavage product produced in comparison to a control, where
15 beta-secretase mediated cleavage in the reaction system is observed and measured in the absence of inhibitory compounds.

Beta-Secretase

Various forms of beta-secretase enzyme are known, and are available and useful for assay of enzyme activity and
20 inhibition of enzyme activity. These include native, recombinant, and synthetic forms of the enzyme. Human beta-secretase is known as Beta Site APP Cleaving Enzyme (BACE), Asp2, and memapsin 2, and has been characterized, for example, in U.S. Patent No. 5,744,346 and published PCT patent
25 applications WO98/22597, WO00/03819, WO01/23533, and WO00/17369, as well as in literature publications (Hussain et al., 1999, *Mol. Cell. Neurosci.* 14:419-427; Vassar et al., 1999, *Science* 286:735-741; Yan et al., 1999, *Nature* 402:533-537; Sinha et al., 1999, *Nature* 40:537-540; and Lin et al.,
30 2000, *PNAS USA* 97:1456-1460). Synthetic forms of the enzyme have also been described (WO98/22597 and WO00/17369). Beta-secretase can be extracted and purified from human brain tissue and can be produced in cells, for example mammalian cells expressing recombinant enzyme.

Preferred compounds are effective to inhibit 50% of beta-secretase enzymatic activity at a concentration of less than 50 micromolar, preferably at a concentration of 10 micromolar or less, more preferably 1 micromolar or less, and most preferably 10 nanomolar or less.

APP Substrate

Assays that demonstrate inhibition of beta-secretase-mediated cleavage of APP can utilize any of the known forms of APP, including the 695 amino acid "normal" isotype described by Kang et al., 1987, *Nature* 325:733-6, the 770 amino acid isotype described by Kitaguchi et. al., 1981, *Nature* 331:530-532, and variants such as the Swedish Mutation (KM670-1NL) (APP-SW), the London Mutation (V7176F), and others. See, for example, U.S. Patent No. 5,766,846 and also Hardy, 1992, *Nature Genet.* 1:233-234, for a review of known variant mutations. Additional useful substrates include the dibasic amino acid modification, APP-KK disclosed, for example, in WO 00/17369, fragments of APP, and synthetic peptides containing the beta-secretase cleavage site, wild type (WT) or mutated form, e.g., SW, as described, for example, in U.S. Patent No 5,942,400 and WO00/03819.

The APP substrate contains the beta-secretase cleavage site of APP (KM-DA or NL-DA) for example, a complete APP peptide or variant, an APP fragment, a recombinant or synthetic APP, or a fusion peptide. Preferably, the fusion peptide includes the beta-secretase cleavage site fused to a peptide having a moiety useful for enzymatic assay, for example, having isolation and/or detection properties. A useful moiety may be an antigenic epitope for antibody binding, a label or other detection moiety, a binding substrate, and the like.

Antibodies

Products characteristic of APP cleavage can be measured by immunoassay using various antibodies, as described, for example, in Pirttila et al., 1999, *Neuro. Lett.* 249:21-4, and

in U.S. Patent No. 5,612,486. Useful antibodies to detect A beta include, for example, the monoclonal antibody 6E10 (Senetek, St. Louis, MO) that specifically recognizes an epitope on amino acids 1-16 of the A beta peptide; antibodies 162 and 164 (New York State Institute for Basic Research, Staten Island, NY) that are specific for human A beta 1-40 and 1-42, respectively; and antibodies that recognize the junction region of beta-amyloid peptide, the site between residues 16 and 17, as described in U.S. Patent No. 5,593,846. Antibodies raised against a synthetic peptide of residues 591 to 596 of APP and SW192 antibody raised against 590-596 of the Swedish mutation are also useful in immunoassay of APP and its cleavage products, as described in U.S. Patent Nos. 5,604,102 and 5,721,130.

Assay Systems

Assays for determining APP cleavage at the beta-secretase cleavage site are well known in the art. Exemplary assays, are described, for example, in U.S. Patent Nos. 5,744,346 and 5,942,400, and described in the Examples below.

Cell Free Assays

Exemplary assays that can be used to demonstrate the inhibitory activity of the compounds of the invention are described, for example, in WO00/17369, WO 00/03819, and U.S. Patents No. 5,942,400 and 5,744,346. Such assays can be performed in cell-free incubations or in cellular incubations using cells expressing a beta-secretase and an APP substrate having a beta-secretase cleavage site.

An APP substrate containing the beta-secretase cleavage site of APP, for example, a complete APP or variant, an APP fragment, or a recombinant or synthetic APP substrate containing the amino acid sequence: KM-DA or NL-DA, is incubated in the presence of beta-secretase enzyme, a fragment thereof, or a synthetic or recombinant polypeptide variant having beta-secretase activity and effective to cleave the beta-secretase cleavage site of APP, under incubation

conditions suitable for the cleavage activity of the enzyme. Suitable substrates optionally include derivatives that may be fusion proteins or peptides that contain the substrate peptide and a modification useful to facilitate the purification or
5 detection of the peptide or its beta-secretase cleavage products. Useful modifications include the insertion of a known antigenic epitope for antibody binding; the linking of a label or detectable moiety, the linking of a binding substrate, and the like.

10 Suitable incubation conditions for a cell-free *in vitro* assay include, for example: approximately 200 nanomolar to 10 micromolar substrate, approximately 10 to 200 picomolar enzyme, and approximately 0.1 nanomolar to 10 micromolar inhibitor compound, in aqueous solution, at an approximate pH
15 of 4 -7, at approximately 37 degrees C, for a time period of approximately 10 minutes to 3 hours. These incubation conditions are exemplary only, and can be varied as required for the particular assay components and/or desired measurement system. Optimization of the incubation conditions for the
20 particular assay components should account for the specific beta-secretase enzyme used and its pH optimum, any additional enzymes and/or markers that might be used in the assay, and the like. Such optimization is routine and will not require undue experimentation.

25 One useful assay utilizes a fusion peptide having maltose binding protein (MBP) fused to the C-terminal 125 amino acids of APP-SW. The MBP portion is captured on an assay substrate by anti-MBP capture antibody. Incubation of the captured fusion protein in the presence of beta-secretase results in
30 cleavage of the substrate at the beta-secretase cleavage site. Analysis of the cleavage activity can be, for example, by immunoassay of cleavage products. One such immunoassay detects a unique epitope exposed at the carboxy terminus of the cleaved fusion protein, for example, using the antibody

SW192. This assay is described, for example, in U.S. Patent No 5,942,400.

Cellular Assay

Numerous cell-based assays can be used to analyze beta-secretase activity and/or processing of APP to release A beta. Contact of an APP substrate with a beta-secretase enzyme within the cell and in the presence or absence of a compound inhibitor of the invention can be used to demonstrate beta-secretase inhibitory activity of the compound. Preferably, assay in the presence of a useful inhibitory compound provides at least about 30%, most preferably at least about 50% inhibition of the enzymatic activity, as compared with a non-inhibited control.

In one embodiment, cells that naturally express beta-secretase are used. Alternatively, cells are modified to express a recombinant beta-secretase or synthetic variant enzyme as discussed above. The APP substrate may be added to the culture medium and is preferably expressed in the cells. Cells that naturally express APP, variant or mutant forms of APP, or cells transformed to express an isoform of APP, mutant or variant APP, recombinant or synthetic APP, APP fragment, or synthetic APP peptide or fusion protein containing the beta-secretase APP cleavage site can be used, provided that the expressed APP is permitted to contact the enzyme and enzymatic cleavage activity can be analyzed.

Human cell lines that normally process A beta from APP provide a useful means to assay inhibitory activities of the compounds of the invention. Production and release of A beta and/or other cleavage products into the culture medium can be measured, for example by immunoassay, such as Western blot or enzyme-linked immunoassay (EIA) such as by ELISA.

Cells expressing an APP substrate and an active beta-secretase can be incubated in the presence of a compound inhibitor to demonstrate inhibition of enzymatic activity as compared with a control. Activity of beta-secretase can be

measured by analysis of one or more cleavage products of the APP substrate. For example, inhibition of beta-secretase activity against the substrate APP would be expected to decrease release of specific beta-secretase induced APP cleavage products such as A beta.

Although both neural and non-neural cells process and release A beta, levels of endogenous beta-secretase activity are low and often difficult to detect by EIA. The use of cell types known to have enhanced beta-secretase activity, enhanced processing of APP to A beta, and/or enhanced production of A beta are therefore preferred. For example, transfection of cells with the Swedish Mutant form of APP (APP-SW); with APP-KK; or with APP-SW-KK provides cells having enhanced beta-secretase activity and producing amounts of A beta that can be readily measured.

In such assays, for example, the cells expressing APP and beta-secretase are incubated in a culture medium under conditions suitable for beta-secretase enzymatic activity at its cleavage site on the APP substrate. On exposure of the cells to the compound inhibitor, the amount of A beta released into the medium and/or the amount of CTF99 fragments of APP in the cell lysates is reduced as compared with the control. The cleavage products of APP can be analyzed, for example, by immune reactions with specific antibodies, as discussed above.

Preferred cells for analysis of beta-secretase activity include primary human neuronal cells, primary transgenic animal neuronal cells where the transgene is APP, and other cells such as those of a stable 293 cell line expressing APP, for example, APP-SW.

In vivo Assays: Animal Models

Various animal models can be used to analyze beta-secretase activity and /or processing of APP to release A beta, as described above. For example, transgenic animals expressing APP substrate and beta-secretase enzyme can be used to demonstrate inhibitory activity of the compounds of the

invention. Certain transgenic animal models have been described, for example, in U.S. Patent Nos.: 5,877,399; 5,612,486; 5,387,742; 5,720,936; 5,850,003; 5,877,015,, and 5,811,633, and in Ganes et al., 1995, *Nature* 373:523.

5 Preferred are animals that exhibit characteristics associated with the pathophysiology of AD. Administration of the compound inhibitors of the invention to the transgenic mice described herein provides an alternative method for demonstrating the inhibitory activity of the compounds.
10 Administration of the compounds in a pharmaceutically effective carrier and via an administrative route that reaches the target tissue in an appropriate therapeutic amount is also preferred.

Inhibition of beta-secretase mediated cleavage of APP at
15 the beta-secretase cleavage site and of A beta release can be analyzed in these animals by measure of cleavage fragments in the animal's body fluids such as cerebral fluid or tissues. Analysis of brain tissues for A beta deposits or plaques is preferred.

20 On contacting an APP substrate with a beta-secretase enzyme in the presence of an inhibitory compound of the invention and under conditions sufficient to permit enzymatic mediated cleavage of APP and/or release of A beta from the substrate, the compounds of the invention are effective to
25 reduce beta-secretase-mediated cleavage of APP at the beta-secretase cleavage site and/or effective to reduce released amounts of A beta. Where such contacting is the administration of the inhibitory compounds of the invention to an animal model, for example, as described above, the
30 compounds are effective to reduce A beta deposition in brain tissues of the animal, and to reduce the number and/or size of beta amyloid plaques. Where such administration is to a human subject, the compounds are effective to inhibit or slow the progression of disease characterized by enhanced amounts of A
35 beta, to slow the progression of AD in the, and/or to prevent

onset or development of AD in a patient at risk for the disease.

Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are hereby incorporated by reference for all purposes.

Definitions

The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.

It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" includes a mixture of two or more compounds. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.

Where multiple substituents are indicated as being attached to a structure, it is to be understood that the substituents can be the same or different. Thus for example "R_m optionally substituted with 1, 2 or 3 R_q groups" indicates that R_m is substituted with 1, 2, or 3 R_q groups where the R_q groups can be the same or different.

APP, amyloid precursor protein, is defined as any APP polypeptide, including APP variants, mutations, and isoforms, for example, as disclosed in U.S. Patent No. 5,766,846.

A beta, amyloid beta peptide, is defined as any peptide resulting from beta-secretase mediated cleavage of APP, including peptides of 39, 40, 41, 42, and 43 amino acids, and extending from the beta-secretase cleavage site to amino acids 39, 40, 41, 42, or 43.

Beta-secretase (BACE1, Asp2, Memapsin 2) is an aspartyl protease that mediates cleavage of APP at the amino-terminal

edge of A beta. Human beta-secretase is described, for example, in WO00/17369.

Pharmaceutically acceptable refers to those properties and/or substances that are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

A therapeutically effective amount is defined as an amount effective to reduce or lessen at least one symptom of the disease being treated or to reduce or delay onset of one or more clinical markers or symptoms of the disease.

By "alkyl" and "C₁-C₆ alkyl" in the present invention is meant straight or branched chain alkyl groups having 1-6 carbon atoms, such as, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. It is understood that in cases where an alkyl chain of a substituent (e.g. of an alkyl, alkoxy or alkenyl group) is shorter or longer than 6 carbons, it will be so indicated in the second "C" as, for example, "C₁-C₁₀" indicates a maximum of 10 carbons.

By "alkoxy" and "C₁-C₆ alkoxy" in the present invention is meant straight or branched chain alkyl groups having 1-6 carbon atoms, attached through at least one divalent oxygen atom, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, hexoxy, and 3-methylpentoxy.

By the term "halogen" in the present invention is meant fluorine, bromine, chlorine, and iodine.

"Alkenyl" and "C₂-C₆ alkenyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and from one to three double bonds and includes, for example, ethenyl, propenyl, 1-but-3-enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like.

"Alkynyl" and "C₂-C₆ alkynyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one or two triple bonds and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like.

5 As used herein, the term "cycloalkyl" refers to saturated carbocyclic radicals having three to twelve carbon atoms. The cycloalkyl can be monocyclic, or a polycyclic fused system. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred cycloalkyl groups are
10 cyclopentyl, cyclohexyl, and cycloheptyl. The cycloalkyl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such cycloalkyl groups may be optionally substituted with, for example, C₁-C₆ alkyl, C₁-C₆ alkoxy,
15 halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl or di(C₁-C₆)alkylamino(C₁-C₆)alkyl.

By "aryl" is meant an aromatic carbocyclic group having a
20 single ring (e.g., phenyl) or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or trisubstituted. Preferred aryl groups of the present invention are phenyl, 1-naphthyl, 2-naphthyl, indanyl,
25 indenyl, dihydronaphthyl, fluorenyl, tetralinyl or 6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl. The aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such aryl groups may be optionally substituted with, for
30 example, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl or di(C₁-C₆)alkylamino(C₁-C₆)alkyl.

By "heteroaryl" is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings which includes fused ring systems of 9-11 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.

5 Preferred heteroaryl groups of the present invention include pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl,

10 indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl, beta-carbolinyl, isochromanlyl, chromanlyl, tetrahydroisoquinolinyl, isoindolinyl,

15 isobenzotetrahydrofuranlyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranlyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, pyridinyl-N-oxide, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl,

25 dihydroisocoumarinyl, dihydroc coumarinyl, dihydroisocoumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl N-oxide,, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolinyl N-oxide, indolyl N-oxide, indolinyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide,

35

benzothiopyranyl S,S-dioxide, tetrahydrocarbazole, tetrahydrobetacarboline. The heteroaryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, 5 such heteroaryl groups may be optionally substituted with, for example, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl or di(C₁- 10 C₆)alkylamino(C₁-C₆)alkyl.

By "heterocycle", "heterocycloalkyl" or "heterocyclyl" is meant one or more carbocyclic ring systems of 4-, 5-, 6-, or 7-membered rings which includes fused ring systems of 9-11 atoms containing at least one and up to four heteroatoms 15 selected from nitrogen, oxygen, or sulfur. Preferred heterocycles of the present invention include morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, 20 tetrahydrothienyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl S-oxide, 25 tetrahydrothienyl S,S-dioxide and homothiomorpholinyl S-oxide. The heterocycle groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. For example, such heterocycle groups may be optionally substituted with, for example, C₁-C₆ alkyl, C₁-C₆ 30 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, C₂-C₆alkenyl, C₂-C₆alkynyl, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, amino(C₁-C₆)alkyl, mono(C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl or =O.

All patents and publications referred to herein are hereby incorporated by reference for all purposes.

Structures were named using Name Pro IUPAC Naming Software, version 5.09, available from Advanced Chemical Development, Inc., 90 Adelaide Street West, Toronto, Ontario, M5H 3V9, Canada, or with Chemdraw Ultra, version 8.0.3, available from CambridgeSoft Corporation, Cambridge, MA 02140, USA.

The present invention may be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention.

15 CHEMISTRY EXAMPLES

The following abbreviations may be used in the Examples:

EDC stands for 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or the hydrochloride salt;

DIEA stands for diisopropylethylamine;

20 PyBOP stands for benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate;

HATU stands for O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate;


THF stands for tetrahydrofuran;

25 EtBz stands for ethylbenzene;

DCM stands for dichloromethane.


Example 1. 1-(3-Ethyl-phenyl)-cyclohexanol from 1-bromo-3-ethylbenzene

30



Magnesium turnings (1.35g, 55.53mmol) were activated via vigorous stirring overnight under N₂ (g) inlet. A few crystals of iodine were added to the flask, which was then flamed-dried under vacuum. Anhydrous THF (3 mL) was added to the reaction flask followed by 1-bromo-3-ethylbenzene (Avocado, 2.0mL, 14.59 mmol). The reaction was initiated after briefly heating with a heat gun. To this was added the remainder of 1-bromo-3-ethylbenzene (1.7mL, 12.43mmol) in a THF solution (15mL). The reaction mixture was refluxed for 2h. A cyclohexanone (2.2mL, 21.22mmol) in THF (8mL) solution was added once the flask was cooled to 0°C. After 3.5h the reaction mixture was quenched with H₂O over an ice bath and partitioned between Et₂O and H₂O. The organic layer was removed and acidified with 1N HCl. The organic layer was separated, dried (Na₂SO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (100% CHCl₃) to give the desired alcohol (4.152g, 96%): mass spec (CI) 187.1 (M-16).


Example 2. 1-(1-Azido-cyclohexyl)-3-ethyl-benzene from 1-(3-Ethyl-phenyl)-cyclohexanol



1-(3-Ethyl-phenyl)-cyclohexanol (4.02g, 19.68mmol) in anhydrous chloroform (45mL) was cooled to 0°C under N₂ (g) inlet. Sodium azide (3.97g, 61.07mmol) was added followed by dropwise addition of trifluoroacetic acid (7.8mL, 101.25mmol).


The reaction mixture was refluxed for 2h and allowed to stir at rt o/n. This was then partitioned between H₂O and Et₂O. The aqueous layer was removed and the mixture was washed with H₂O followed by 1.0N NH₄OH. The organic layer was separated, dried (Na₂SO₄), and concentrated under reduced pressure. The crude product was used without further purification (3.30g, 73%): mass spec (CI) 187.1 (M-42).

Example 3. 1-(3-Ethyl-phenyl)-cyclohexylamine from 1-(1-azido-cyclohexyl)-3-ethyl-benzene



A solution of 1-(1-azido-cyclohexyl)-3-ethyl-benzene (1.94g, 8.39mmol) in Et₂O (8mL) was added dropwise to a suspension of lithium aluminum hydride (0.31g, 8.17mmol) in THF (30mL). This was stirred at rt under N₂ (g) inlet for 3h, whereupon the reaction was quenched with 1.0N NaOH. The reaction mixture was then partitioned between EtO₂ and 1N HCl. The aqueous layer was collected and basified with 2N NH₄OH and extracted with CHCl₃. The organic layer was separated, dried (Na₂SO₄), and concentrated under reduced pressure. The crude product was used without further purification: mass spec (CI) 187.1 (M-16).

Example 4. Preparation of 7-Bromo-1-tetralone (note 1)




A 500 mL three-necked flask fitted with an addition funnel, reflux condenser and thermometer was charged with

aluminum chloride (33.34 g, 250 mmol) and heated to 75-80 °C. 1-Tetralone (14.6 g, 13.3 mL, 100 mmol) was added dropwise over 10 min. The resulting brown slurry was stirred for 3 min before dropwise addition of bromine (19.21 g, 6.15 ml, 120 mmol) over 15 min. The mixture was stirred for 5 min and then poured into a mixture of ice (300 g) and 12N HCl (40 mL). The mixture was stirred until the aluminum chloride was dissolved and then diluted with water (200 mL). The mixture was extracted with diethyl ether (3 X 300 mL) and the combined organics were washed with water (2 X 300 mL), dried (sodium sulfate), filtered and evaporated *in vacuo* to give a dark brown mixture of 5- and 7-bromo-1-tetralone. The isomers were separated using silica gel flash chromatography (Biotage Flash 75, elution solvent 20/1 hexanes:MTBE) to yield 5-bromo-1-tetralone (11.59 g, 51%) and 7-bromo-1-tetralone (9.45 g, 42%).

[Note 1. Procedure: Cornelius, L. A.M.; Combs, D. W. *Synthetic Communications* **1994**, *24*, 2777-2788].

Example 5. (R)-7-Ethyltetralin-1-ol (see note 2)



20

7-Ethyl-1-tetralone (2.29 g, 13.1 mmol) was placed in a 100 mL round bottomed flask and dissolved in anhydrous THF (40 mL). Activated 4A molecular sieves were added and the mixture was aged for 2 h before transferring via cannula to a 250 mL three-necked round bottom flask fitted with a dropping funnel, thermometer, and a nitrogen inlet. The solution was cooled to -25°C and 1M (S)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole in toluene (1.3 mL, 1.3 mmol, notes 3 and 4) was added.

30

The dropping funnel was charged with a solution of borane-methylsulfide (0.70 g, 0.87 mL, 9.3 mmol) in anhydrous THF (15 mL, dried over 4A sieves). The borane solution was added dropwise over 20 min keeping the reaction temperature less than -20 °C. The mixture was stirred for 1 h at -15 to -20 °C whereupon TLC analysis indicated consumption of the ketone. The reaction was quenched by careful addition of methanol (15 mL) at -20 °C and allowed to warm to ambient temperature and stir for 16 h. The volatiles were removed in vacuo and the residue was purified by silica gel chromatography (Biotage Flash 65, elution solvent 6/1 hexanes:ethyl acetate) to yield (R)-7-ethyltetralin-1-ol (1.82 g, 79%, note 5).


[Note 2. Procedure adapted from: Jones, T. K.; Mohan, J. J.; Xavier, L. C.; Blacklock, T. J.; Mathre, D. J.; Sohar, P.; Turner-Jones, E. T.; Reamer, R. A.; Roberts, F. E.; Grabowski, E. J. J. *J. Org. Chem.* **1991**, *56*, 763-769.

Note 3. Source: Aldrich cat. # 45,770-1, "(S)-2-methyl-CBS-oxazaborolidine". Use of the S-auxilliary produces R-alcohols.

Note 4. The reference in note 1 indicates that use of 5 mol% oxazaborolidine catalyst gives comparable results.

Note 5. Analytical chiral HPLC indicated a 96.6/3.4 mixture of enantiomers (Chirocel OD-H column, isocratic elution 2:98 IPA/hexane, 0.9 mL/min, RT 15.2 min (minor enantiomer), 17.5 min (major enantiomer)].

Example 6. (S)-7-Ethyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride (see note 6).



A solution of (R)-7-ethyltetralin-1-ol (1.77 g, 10.1 mmol) in toluene (25 mL) was cooled in an ice bath and treated with diphenylphosphoryl azide (DPPA, 3.3 g, 2.7 mL, 12 mmol). A solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 1.8 g, 1.8 mL, 12 mmol) in toluene (8 mL) was added over 20 min and the mixture was allowed to stir at 0 °C for 2 h and ambient temp for 16 h. The mixture was filtered through a pad of silica gel (eluted 6:1 hexanes/ethyl acetate) to remove precipitates and the volatiles were removed *in vacuo* to give an oily residue of the crude S-azide. This material was used directly in the next step without further characterization.


The azide was dissolved in dry THF (20 mL) and added dropwise at RT to a slurry of lithium aluminum hydride (0.459 g, 12 mmol) in dry THF (20 mL). The mixture was stirred at RT for 1 h and then heated to reflux for 1 h. The reaction was cooled to RT and quenched by successive addition of water (0.45 mL), 15% aq NaOH (0.45 mL) and water (1.4 mL). The resulting mixture was stirred for 1 h and then filtered through a pad of Celite (eluted diethyl ether). The volatiles were removed *in vacuo* and the residue taken up into ethyl acetate (40 mL) and treated with 4N HCl in dioxane (3 mL). The resulting precipitate was filtered (wash ethyl acetate), collected and vacuum dried to give (S)-7-ethyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride as a white solid (1.09 g, 51%, note 7).

[Note 6. Procedure adapted from: Rover, S.; Adam, G.; Cesura, A. M.; Galley, G.; Jenck, F.; Monsma Jr., F. J.; Wichmann, J.; Dautzenberg, F. M. *J. Med. Chem.* **2000**, *43*, 1329-1338. Authors report a somewhat diminished yield due to

partial formation of a dihydronaphthalene via elimination of the hydroxyl moiety].

[Note 7. Analytical chiral HPLC indicated a 96:4 mixture of enantiomers (Daicel Crownpak (-) column, isocratic elution 10% methanol in water (0.1% TFA), 0.8 mL/min, RT 56.2 min (minor enantiomer), 78.2 min (major enantiomer))].

Example 7. (R)-7-Bromotetralin-1-ol (see note 8)



10

7-Bromo-1-tetralone (8.28 g, 36.8 mmol) was placed in a 250 mL round bottomed flask and dissolved in anhydrous THF (100 mL). Activated 4A molecular sieves were added and the mixture was aged for 5 h before transferring via cannula to a 500 ml three-necked round bottom flask fitted with a dropping funnel, thermometer, and a nitrogen inlet. The solution was cooled to -25°C and 1M (S)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole in toluene (3.7 mL, 3.7 mmol, notes 9 and 10) was added.

The dropping funnel was charged with a solution of borane-methylsulfide (1.96 g, 2.44 mL, 25.8 mmol) in anhydrous THF (45 mL, dried over 4A sieves). The borane solution was added dropwise over 20 min keeping the reaction temperature less than -20°C . The mixture was stirred for 1 h at -15 to -20°C whereupon TLC analysis indicated consumption of the ketone. The reaction was quenched by careful addition of methanol (50 mL) at -20°C and allowed to warm to ambient temperature and stir for 16h. The volatiles were removed in vacuo and the residue was purified by silica gel chromatography (Biotage Flash 65, elution solvent 6/1

hexanes:ethyl acetate) to yield (R)-7-bromotetralin-1-ol (8.18 g, 98%, notes 11 and 12).

[Note 8. Procedure adapted from: Jones, T. K.; Mohan, J. J.; Xavier, L. C.; Blacklock, T. J.; Mathre, D. J.; Sohar, P.;
5 Turner-Jones, E. T.; Reamer, R. A.; Roberts, F. E.; Grabowski, E. J. J. *J. Org. Chem.* **1991**, 56, 763-769.

Note 9. Source: Aldrich cat. # 45,770-1, "(S)-2-methyl-CBS-oxazaborolidine". Use of the S-auxilliary produces R-alcohols.


10 Note 10. The reference in note 1 indicates that use of 5 mol% oxazaborolidine catalyst gives comparable results.

Note 11. Analytical chiral HPLC indicated a 98:2 mixture of enantiomers (Chirocel OD-H column, isocratic elution 2:98 IPA/hexane, 0.9 mL/min, RT 18.4 min (minor enantiomer), 19.5
15 min (major enantiomer).

Note 12. Proton NMR was consistent with that previously reported for the racemate: Saito, M.; Kayama, Y.; Watanabe, T.; Fukushima, H.; Hara, T. *J. Med. Chem.* **1980**, 23, 1364-1372].

20

Example 8. (S)-7-Bromo-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride, (see note 13).



25 A solution of (R)-7-bromotetralin-1-ol (8.13 g, 35.8 mmol) in toluene (75 mL) was cooled in an ice bath and treated with diphenylphosphoryl azide (DPPA, 11.8 g, 9.6 mL, 43 mmol). A solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 6.5 g, 6.4 mL, 43 mmol) in toluene (20 mL) was added over 35 min and
30 the mixture was allowed to stir at 0 °C for 2 h and ambient temp for 16 h. The mixture was filtered through a pad of

silica gel (eluted 6:1 hexanes/ethyl acetate) to remove precipitates and the volatiles were removed *in vacuo* to give an oily residue of the crude S-azide. This material was used directly in the next step without further characterization.

5 The azide was dissolved in dry THF (60 mL) and added dropwise at RT to a slurry of lithium aluminum hydride (1.63g, 43 mmol) in dry THF (50 mL). The mixture was stirred at RT for 1h and then heated to reflux for 1 h. The reaction was cooled to RT and quenched by successive addition of water
10 (1.63 mL), 15% aq NaOH (1.63 mL) and water (4.9 mL). The resulting mixture was stirred for 1 h and then filtered through a pad of Celite (eluted diethyl ether). The volatiles were removed *in vacuo* and the residue taken up into ethyl acetate (120 mL) and treated with 4N HCl in dioxane (10 mL).
15 The resulting precipitate was filtered (wash ethyl acetate), collected and vacuum dried to give (S)-7-bromo-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride as a white solid (6.23 g, 66.3%, note 14).

[Note 13. Procedure adapted from: Rover, S.; Adam, G.;
20 Cesura, A. M.; Galley, G.; Jenck, F.; Monsma Jr., F. J.; Wichmann, J.; Dautzenberg, F. M. *J. Med. Chem.* **2000**, *43*, 1329-1338. Authors report a somewhat diminished yield due to partial formation of a dihydronaphthalene via elimination of the hydroxyl moiety


25 Note 14. Analytical chiral HPLC indicated a 96:4 mixture of enantiomers (Daicel Crownpak (-) column, isocratic elution 10% methanol in water (0.1% TFA), 0.8 mL/min, RT 39.4 min (minor enantiomer), 57.6 min (major enantiomer)].

The following compounds are prepared essentially
30 according to the procedures described in the schemes, charts, examples and preparations set forth herein.

Ex. No.

Compound

9



mass spec: 480.2

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{{[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)pyridine-2-carboxamide,


10

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{{[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)pyrazine-2-carboxamide (mass spec: 481.2),

11

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-{{[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)-1-ethyl-3-methyl-1*H*-pyrazole-5-carboxamide (mass spec: 511.2),


12



mass spec: 485.2

3-amino-*N*-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-([(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)-1*H*-1,2,4-triazole-5-carboxamide,


13



mass spec: 484.2

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-([(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)-5-methylisoxazole-3-carboxamide,

14



mass spec: 496.2


N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-([(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)-6-hydroxypyridine-2-carboxamide,

15

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-([(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino)-2-hydroxypropyl)-1*H*-imidazole-4-carboxamide (mass spec:

469.2),

16



mass spec: 480.2

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-({[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)nicotinamide,


17

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-({[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)-1*H*-pyrazole-4-carboxamide (mass spec: 469.2),

18

N-((1*S*,2*R*)-1-(3,5-difluorobenzyl)-3-({[(1*S*)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)isonicotinamide (mass spec: 480.2),

19




mass spec: 520.1

5-chloro-N-((1S,2R)-1-(3,5-difluorobenzyl)-3-({[(1S)-7-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-2-hydroxypropyl)thiophene-2-carboxamide.

20

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propyl)benzamide,

21



N-[(1S,2R)-3-({[(4S)-6-tert-butoxy-3,4-dihydro-2H-chromen-4-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

22


N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({[(4S)-6-neopentyl-1,2,3,4-tetrahydroquinolin-4-yl]amino}propyl)benzamide,

23

N-[(1S,2R)-3-({[(4S)-6-tert-butoxy-1,2,3,4-

tetrahydroquinolin-4-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

24



N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({[(1S)-7-neopentyl-1,2,3,4-tetrahydronaphthalen-1-yl]amino}propyl)benzamide,


25

N-[(1S,2R)-3-({[(1S)-7-tert-butoxy-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

26

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({[(4R)-6-neopentyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}propyl)benzamide,

27



N-[(1S,2R)-3-({[(4R)-6-tert-butoxy-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,


28

N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-([1-(3-

neopentylphenyl)cyclohexyl]amino}propyl)benzamide,

29 N-[(1S,2R)-3-{[1-(3-tert-butoxyphenyl)cyclohexyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

30 N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[1-(3-neopentylphenyl)cyclopropyl]amino}propyl]benzamide,




N-[(1S,2R)-3-{[1-(3-tert-butoxyphenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

32 N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4-tert-butoxy-1,1'-biphenyl-2-yl)methyl]amino}propyl]benzamide,

33 N-[(1S,2R)-3-{[(4-tert-butoxy-1,1'-biphenyl-2-yl)methyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]benzamide,

34




N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-((2-neopentyl-9H-fluoren-9-yl)amino)propyl)benzamide,

35

N-((1S,2R)-3-((2-tert-butoxy-9H-fluoren-9-yl)amino)-1-(3,5-difluorobenzyl)-2-hydroxypropyl)benzamide.

36



mass
spec

557.2

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-(((4R)-6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino)-2-hydroxypropyl)-3,5-dimethylbenzamide

37

N-((1S,2R)-1-(3,5-difluorobenzyl)-3-(((4R)-6-ethyl-2,2-dioxido-3,4-dihydro-1H-isothiochromen-4-yl)amino)-2-hydroxypropyl)-4-(2-methoxyethyl)benzamide

587.2

BIOLOGY EXAMPLES

Example A

Enzyme Inhibition Assay

The compounds of the invention are analyzed for
5 inhibitory activity by use of the MBP-C125 assay. This assay
determines the relative inhibition of beta-secretase cleavage
of a model APP substrate, MBP-C125SW, by the compounds assayed
as compared with an untreated control. A detailed description
of the assay parameters can be found, for example, in U.S.
10 Patent No. 5,942,400. Briefly, the substrate is a fusion
peptide formed of maltose binding protein (MBP) and the
carboxy terminal 125 amino acids of APP-SW, the Swedish
mutation. The beta-secretase enzyme is derived from human
brain tissue as described in Sinha et al, 1999, *Nature* 40:537-
15 540) or recombinantly produced as the full-length enzyme
(amino acids 1-501), and can be prepared, for example, from
293 cells expressing the recombinant cDNA, as described in
WO00/47618.

Inhibition of the enzyme is analyzed, for example, by
20 immunoassay of the enzyme's cleavage products. One exemplary
ELISA uses an anti-MBP capture antibody that is deposited on
precoated and blocked 96-well high binding plates, followed by
incubation with diluted enzyme reaction supernatant,
incubation with a specific reporter antibody, for example,
25 biotinylated anti-SW192 reporter antibody, and further
incubation with streptavidin/alkaline phosphatase. In the
assay, cleavage of the intact MBP-C125SW fusion protein
results in the generation of a truncated amino-terminal
fragment, exposing a new SW-192 antibody-positive epitope at
30 the carboxy terminus. Detection is effected by a fluorescent
substrate signal on cleavage by the phosphatase. ELISA only
detects cleavage following Leu 596 at the substrate's APP-SW
751 mutation site.

Specific Assay Procedure:

Compounds are diluted in a 1:1 dilution series to a six-point concentration curve (two wells per concentration) in one 96-plate row per compound tested. Each of the test compounds is prepared in DMSO to make up a 10 millimolar stock solution.

5 The stock solution is serially diluted in DMSO to obtain a final compound concentration of 200 micromolar at the high point of a 6-point dilution curve. Ten (10) microliters of each dilution is added to each of two wells on row C of a corresponding V-bottom plate to which 190 microliters of 52

10 millimolar NaOAc, 7.9% DMSO, pH 4.5 are pre-added. The NaOAc diluted compound plate is spun down to pellet precipitant and 20 microliters/well is transferred to a corresponding flat-bottom plate to which 30 microliters of ice-cold enzyme-substrate mixture (2.5 microliters MBP-C125SW substrate, 0.03

15 microliters enzyme and 24.5 microliters ice cold 0.09% TX100 per 30 microliters) is added. The final reaction mixture of 200 micromolar compound at the highest curve point is in 5% DMSO, 20 millimolar NaOAc, 0.06% TX100, at pH 4.5.

Warming the plates to 37 degrees C starts the enzyme

20 reaction. After 90 minutes at 37 degrees C, 200 microliters/well cold specimen diluent is added to stop the reaction and 20 microliters/well was transferred to a corresponding anti-MBP antibody coated ELISA plate for capture, containing 80 microliters/well specimen diluent.

25 This reaction is incubated overnight at 4 degrees C and the ELISA is developed the next day after a 2 hour incubation with anti-192SW antibody, followed by Streptavidin-AP conjugate and fluorescent substrate. The signal is read on a fluorescent plate reader.

30 Relative compound inhibition potency is determined by calculating the concentration of compound that showed a fifty percent reduction in detected signal (IC_{50}) compared to the enzyme reaction signal in the control wells with no added compound. In this assay, preferred compounds of the invention

35 exhibit an IC_{50} of less than 50 micromolar.

Example B

Cell Free Inhibition Assay Utilizing a Synthetic APP

Substrate

A synthetic APP substrate that can be cleaved by beta-secretase and having N-terminal biotin and made fluorescent by the covalent attachment of Oregon green at the Cys residue is used to assay beta-secretase activity in the presence or absence of the inhibitory compounds of the invention. Useful substrates include the following:

10

Biotin-SEVNL-DAEFRC[oregon green]KK

[SEQ ID NO: 1]

Biotin-SEVKM-DAEFRC[oregon green]KK

[SEQ ID NO: 2]

15

Biotin-GLNIKTEEISEISY-EVEFRC[oregon green]KK

[SEQ ID

NO: 3]

Biotin-ADRGLTTRPGSGLTNIKTEEISEVNL-DAEFRC
[oregon green]KK

[SEQ ID

NO:4]

20

Biotin-FVNQHLCoxGSHLVEALY-LVCoxGERGFFYTPKAC
[oregon green]KK

[SEQ ID

NO: 5]

25

The enzyme (0.1 nanomolar) and test compounds (0.001 - 100 micromolar) are incubated in pre-blocked, low affinity, black plates (384 well) at 37 degrees for 30 minutes. The reaction is initiated by addition of 150 millimolar substrate to a final volume of 30 microliter per well. The final assay conditions are: 0.001 - 100 micromolar compound inhibitor; 0.1 molar sodium acetate (pH 4.5); 150 nanomolar substrate; 0.1 nanomolar soluble beta-secretase; 0.001% Tween 20, and 2% DMSO. The assay mixture is incubated for 3 hours at 37 degrees C, and the reaction is terminated by the addition of a saturating concentration of immunopure streptavidin. After incubation with streptavidin at room temperature for 15 minutes, fluorescence polarization is measured, for example, using a LJL Acquest (Ex485 nm/ Em530 nm). The activity of

30

35

the beta-secretase enzyme is detected by changes in the fluorescence polarization that occur when the substrate is cleaved by the enzyme. Incubation in the presence or absence of compound inhibitor demonstrates specific inhibition of beta-secretase enzymatic cleavage of its synthetic APP substrate. In this assay, preferred compounds of the invention exhibit an IC_{50} of less than 50 micromolar. More preferred compounds of the invention exhibit an IC_{50} of less than 10 micromolar. Even more preferred compounds of the invention exhibit an IC_{50} of less than 5 micromolar.

Example C

Beta-Secretase Inhibition: P26-P4'SW Assay

Synthetic substrates containing the beta-secretase cleavage site of APP are used to assay beta-secretase activity, using the methods described, for example, in published PCT application WO00/47618. The P26-P4'SW substrate is a peptide of the sequence:

(biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNLDAEF [SEQ ID NO:

6]

The P26-P1 standard has the sequence:

(biotin)CGGADRGLTTRPGSGLTNIKTEEISEVNL [SEQ ID NO:

7].

Briefly, the biotin-coupled synthetic substrates are incubated at a concentration of from about 0 to about 200 micromolar in this assay. When testing inhibitory compounds, a substrate concentration of about 1.0 micromolar is preferred. Test compounds diluted in DMSO are added to the reaction mixture, with a final DMSO concentration of 5%. Controls also contain a final DMSO concentration of 5%. The concentration of beta secretase enzyme in the reaction is varied, to give product concentrations with the linear range of the ELISA assay, about 125 to 2000 picomolar, after dilution.

The reaction mixture also includes 20 millimolar sodium acetate, pH 4.5, 0.06% Triton X100, and is incubated at 37

degrees C for about 1 to 3 hours. Samples are then diluted in assay buffer (for example, 145.4 nanomolar sodium chloride, 9.51 millimolar sodium phosphate, 7.7 millimolar sodium azide, 0.05% Triton X405, 6g/liter bovine serum albumin, pH 7.4) to
5 quench the reaction, then diluted further for immunoassay of the cleavage products.

Cleavage products can be assayed by ELISA. Diluted samples and standards are incubated in assay plates coated with capture antibody, for example, SW192, for about 24 hours
10 at 4 degrees C. After washing in TTBS buffer (150 millimolar sodium chloride, 25 millimolar Tris, 0.05% Tween 20, pH 7.5), the samples are incubated with streptavidin-AP according to the manufacturer's instructions. After a one hour incubation at room temperature, the samples are washed in TTBS and
15 incubated with fluorescent substrate solution A (31.2 g/liter 2-amino-2-methyl-1-propanol, 30 mg/liter, pH 9.5). Reaction with streptavidin-alkaline phosphate permits detection by fluorescence. Compounds that are effective inhibitors of beta-secretase activity demonstrate reduced cleavage of the
20 substrate as compared to a control.

Example D

Assays using Synthetic Oligopeptide-Substrates

Synthetic oligopeptides are prepared that incorporate the known cleavage site of beta-secretase, and optionally
25 detectable tags, such as fluorescent or chromogenic moieties. Examples of such peptides, as well as their production and detection methods are described in U.S. Patent No: 5,942,400, herein incorporated by reference. Cleavage products can be detected using high performance liquid chromatography, or
30 fluorescent or chromogenic detection methods appropriate to the peptide to be detected, according to methods well known in the art.

By way of example, one such peptide has the sequence SEVNL-DAEF [SEQ ID NO: 8], and the cleavage site is between
35 residues 5 and 6. Another preferred substrate has the

sequence ADRGLTTRPGSGLTNIKTEEISEVNL-DAEF [SEQ ID NO: 9], and the cleavage site is between residues 26 and 27.

These synthetic APP substrates are incubated in the presence of beta-secretase under conditions sufficient to result in beta-secretase mediated cleavage of the substrate. Comparison of the cleavage results in the presence of the compound inhibitor to control results provides a measure of the compound's inhibitory activity.

Example E

Inhibition of Beta-Secretase Activity - Cellular Assay

An exemplary assay for the analysis of inhibition of beta-secretase activity utilizes the human embryonic kidney cell line HEKp293 (ATCC Accession No. CRL-1573) transfected with APP751 containing the naturally occurring double mutation Lys651Met52 to Asn651Leu652 (numbered for APP751), commonly called the Swedish mutation and shown to overproduce A beta (Citron et al., 1992, *Nature* 360:672-674), as described in U.S. Patent No. 5,604,102.

The cells are incubated in the presence/absence of the inhibitory compound (diluted in DMSO) at the desired concentration, generally up to 10 micrograms/ml. At the end of the treatment period, conditioned media is analyzed for beta-secretase activity, for example, by analysis of cleavage fragments. A beta can be analyzed by immunoassay, using specific detection antibodies. The enzymatic activity is measured in the presence and absence of the compound inhibitors to demonstrate specific inhibition of beta-secretase mediated cleavage of APP substrate.

Example F

Inhibition of Beta-Secretase in Animal Models of AD

Various animal models can be used to screen for inhibition of beta-secretase activity. Examples of animal models useful in the invention include, but are not limited to, mouse, guinea pig, dog, and the like. The animals used can be wild type, transgenic, or knockout models. In addition,

mammalian models can express mutations in APP, such as APP695-SW and the like described herein. Examples of transgenic non-human mammalian models are described in U.S. Patent Nos. 5,604,102, 5,912,410 and 5,811,633.

5 PDAPP mice, prepared as described in Games et al., 1995, *Nature* 373:523-527 are useful to analyze *in vivo* suppression of A beta release in the presence of putative inhibitory compounds. As described in U.S. Patent No. 6,191,166, 4 month old PDAPP mice are administered compound formulated in
10 vehicle, such as corn oil. The mice are dosed with compound (1-30 mg/ml; preferably 1-10 mg/ml). After time, e.g., 3-10 hours, the animals are sacrificed, and brains removed for analysis.

Transgenic animals are administered an amount of the
15 compound inhibitor formulated in a carrier suitable for the chosen mode of administration. Control animals are untreated, treated with vehicle, or treated with an inactive compound. Administration can be acute, i.e., single dose or multiple doses in one day, or can be chronic, i.e., dosing is repeated
20 daily for a period of days. Beginning at time 0, brain tissue or cerebral fluid is obtained from selected animals and analyzed for the presence of APP cleavage peptides, including A beta, for example, by immunoassay using specific antibodies for A beta detection. At the end of the test period, animals
25 are sacrificed and brain tissue or cerebral fluid is analyzed for the presence of A beta and/or beta-amyloid plaques. The tissue is also analyzed for necrosis.

Animals administered the compound inhibitors of the invention are expected to demonstrate reduced A beta in brain
30 tissues or cerebral fluids and reduced beta amyloid plaques in brain tissue, as compared with non-treated controls.

Example G

Inhibition of A Beta Production in Human Patients

Patients suffering from Alzheimer's Disease (AD)
35 demonstrate an increased amount of A beta in the brain. AD

patients are administered an amount of the compound inhibitor formulated in a carrier suitable for the chosen mode of administration. Administration is repeated daily for the duration of the test period. Beginning on day 0, cognitive and memory tests are performed, for example, once per month.

Patients administered the compound inhibitors are expected to demonstrate slowing or stabilization of disease progression as analyzed by changes in one or more of the following disease parameters: A beta present in CSF or plasma; brain or hippocampal volume; A beta deposits in the brain; amyloid plaque in the brain; and scores for cognitive and memory function, as compared with control, non-treated patients.

Example H

Prevention of A Beta Production in Patients at Risk for AD

Patients predisposed or at risk for developing AD are identified either by recognition of a familial inheritance pattern, for example, presence of the Swedish Mutation, and/or by monitoring diagnostic parameters. Patients identified as predisposed or at risk for developing AD are administered an amount of the compound inhibitor formulated in a carrier suitable for the chosen mode of administration. Administration is repeated daily for the duration of the test period. Beginning on day 0, cognitive and memory tests are performed, for example, once per month.

Patients administered the compound inhibitors are expected to demonstrate slowing or stabilization of disease progression as analyzed by changes in one or more of the following disease parameters: A beta present in CSF or plasma; brain or hippocampal volume; amyloid plaque in the brain; and scores for cognitive and memory function, as compared with control, non-treated patients.

The invention has been described with reference to various specific and preferred embodiments and techniques.

MBHB 03-170-A
PHA 01550.US1
ELN 467-US-NEW

However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.